US20020183378A1 - Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms - Google Patents

Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms Download PDF

Info

Publication number
US20020183378A1
US20020183378A1 US09/997,126 US99712601A US2002183378A1 US 20020183378 A1 US20020183378 A1 US 20020183378A1 US 99712601 A US99712601 A US 99712601A US 2002183378 A1 US2002183378 A1 US 2002183378A1
Authority
US
United States
Prior art keywords
form
calcium
atorvastatin hemi
process
atorvastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/997,126
Inventor
Judith Aronhime
Ramy Lidor-Hadas
Valerie Niddam
Revital Lifshitz
Eti Ishai
Guy Sambursky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US25007200P priority Critical
Priority to US26789701P priority
Priority to US28187201P priority
Priority to US31214401P priority
Priority to US32652901P priority
Priority to US09/997,126 priority patent/US20020183378A1/en
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Assigned to TEVA PHARMACEUTICALS USA, INC. reassignment TEVA PHARMACEUTICALS USA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TEVA PHARMACEUTICAL INDUSTRIES LTD.
Assigned to TEVA PHARMACEUTICAL INDUSTRIES LTD. reassignment TEVA PHARMACEUTICAL INDUSTRIES LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NIDDAM, VALERIE, SAMBURSKY, GUY, ISHAI, ETI, LIDOR-HADAS, RAMY, LIFSHITZ, REVITAL, ARONHIME, JUDITH
Publication of US20020183378A1 publication Critical patent/US20020183378A1/en
Priority claimed from US10/370,897 external-priority patent/US7501450B2/en
Assigned to TEVA PHARMACEUTICAL INDUSTRIES LTD. reassignment TEVA PHARMACEUTICAL INDUSTRIES LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WIZEL, SHLOMIT
Priority claimed from US11/233,310 external-priority patent/US20060020137A1/en
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds

Abstract

The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of provisional applications Serial Nos. 60/250,072, filed Nov. 30, 2000; 60/267,897, filed Feb. 9, 2001; 60/281,872, filed Apr. 5, 2001; 60/312,144, filed Aug. 13, 2001 and 60/326,529, filed Oct. 1, 2001, all of which are incorporated herein by reference.[0001]
  • FIELD OF THE INVENTION
  • The present invention relates to crystalline polymorphic forms of atorvastatin hemi-calcium, novel processes for preparing crystalline forms of atorvastatin hemi-calcium and crystalline atorvastatin hemi-calcium with a small particle size distribution. [0002]
  • BACKGROUND OF THE INVENTION
  • Atorvastatin, ([R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid), depicted in lactone form in formula (I) and its calcium salt trihydrate of formula (II) are well known in the art, and described, inter alia, in U.S. Pat. Nos. 4,681,893, 5,273,995, and in copending U.S. Ser. No. 60/166,153, filed Nov. 17, 2000, all of which are herein incorporated by reference. [0003]
    Figure US20020183378A1-20021205-C00001
  • Atorvastatin is a member of the class of drugs called statins. Statin drugs are currently the most therapeutically effective drugs available for reducing low density lipoprotein (LDL) particle concentration in the blood stream of patients at risk for cardiovascular disease. A high level of LDL in the bloodstream has been linked to the formation of coronary lesions which obstruct the flow of blood and can rupture and promote thrombosis. Goodman and Gilman, [0004] The Pharmacological Basis of Therapeutics 879 (9th ed. 1996). Reducing plasma LDL levels has been shown to reduce the risk of clinical events in patients with cardiovascular disease and patients who are free of cardiovascular disease but who have hypercholesterolemia. Scandinavian Simvastatin Survival Study Group, 1994; Lipid Research Clinics Program, 1984a, 1984b.
  • The mechanism of action of statin drugs has been elucidated in some detail. They interfere with the synthesis of cholesterol and other sterols in the liver by competitively inhibiting the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase enzyme (“HMG-CoA reductase”). HMG-CoA reductase catalyzes the conversion HMG to mevalonate, which is the rate determining step in the biosynthesis of cholesterol, and so, its inhibition leads to a reduction in the concentration of cholesterol in the liver. Very low density lipoprotein (VLDL) is the biological vehicle for transporting cholesterol and triglycerides from the liver to peripheral cells. VLDL is catabolized in the peripheral cells which releases fatty acids which may be stored in adopcytes or oxidized by muscle. The VLDL is converted to intermediate density lipoprotein (IDL), which is either removed by an LDL receptor, or is converted to LDL. Decreased production of cholesterol leads to an increase in the number of LDL receptors and corresponding reduction in the production of LDL particles by metabolism of IDL. [0005]
  • Atorvastatin hemi-calcium salt trihydrate is marketed under the name LIPITOR by Warner-Lambert Co. Atorvastatin was first disclosed to the public and claimed in U.S. Pat. No. 4,681,893. The hemi-calcium salt depicted in formula (II) is disclosed in U.S. Pat. No. 5,273,995. The '995 patent teaches that the hemi-calcium salt is obtained by crystallization from a brine solution resulting from the transposition of the sodium salt with CaCl[0006] 2 and further purified by recrystallization from a 5:3 mixture of ethyl acetate and hexane.
  • The present invention provides new crystal forms of atorvastatin hemi-calcium in both solvated and hydrated states. The occurrence of different crystal forms (polymorphism) is a property of some molecules and molecular complexes. A single molecule, like the atorvastatin in formula (I) or the salt complex of formula (II), may give rise to a variety of solids having distinct physical properties like melting point, X-ray diffraction pattern, infrared absorption fingerprint and NMR spectrum. The differences in the physical properties of polymorphs result from the orientation and intermolecular interactions of adjacent molecules (complexes) in the bulk solid. Accordingly, polymorphs are distinct solids sharing the same molecular formula yet having distinct advantageous and/or disadvantageous physical properties compared to other forms in the polymorph family. One of the most important physical properties of pharmaceutical polymorphs is their solubility in aqueous solution, particularly their solubility in the gastric juices of a patient. For example, where absorption through the gastrointestinal tract is slow, it is often desirable for a drug that is unstable to conditions in the patient's stomach or intestine to dissolve slowly so that it does not accumulate in a deleterious environment. On the other hand, where the effectiveness of a drug correlates with peak bloodstream levels of the drug, a property shared by statin drugs, and provided the drug is rapidly absorbed by the GI system, then a more rapidly dissolving form is likely to exhibit increased effectiveness over a comparable amount of a more slowly dissolving form. [0007]
  • Crystalline Forms I, II, III and IV of atorvastatin hemi-calcium are the subjects of U.S. Pat. Nos. 5,959,156 and 6,121,461 assigned to Warner-Lambert and crystalline atorvastatin hemi-calcium Form V is disclosed in commonly-owned PCT Application No. PCT/US00/31555. There is an assertion in the '156 patent that Form I possesses more favorable filtration and drying characteristics than the known amorphous form of atorvastatin hemi-calcium. Although Form I remedies some of the deficiencies of the amorphous material in terms of manufacturability, there remains a need for yet further improvement in these properties as well as improvements in other properties such as flowability, vapor impermeability and solubility. Further, the discovery of new crystalline polymorphic forms of a drug enlarges the repertoire of materials that a formulation scientist has with which to design a pharmaceutical dosage form of a drug with a targeted release profile or other desired characteristic.[0008]
  • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 is a characteristic powder X-ray diffraction pattern of atorvastatin hemi-calcium Form VI obtained using a conventional X-ray generator with a copper anode. [0009]
  • FIG. 2 is a characteristic powder X-ray diffraction pattern of atorvastatin hemi-calcium Form VII obtained using a conventional X-ray generator with a copper anode. [0010]
  • FIG. 3 is a characteristic powder X-ray diffraction pattern of atorvastatin hemi-calcium Form VIII obtained using a conventional X-ray generator with a copper anode. [0011]
  • FIG. 4 is a characteristic powder X-ray diffraction pattern of atorvastatin hemi-calcium Form VIII obtained using a synchrotron X-ray source. [0012]
  • FIG. 5 is a characteristic solid state [0013] 13C NMR spectrum of atorvastatin Form VIII.
  • FIG. 6 is a characteristic powder X-ray diffraction pattern of atorvastatin hemi-calcium Form IX obtained using a conventional X-ray generator with a copper anode. [0014]
  • FIG. 7 is a characteristic powder X-ray diffraction pattern of atorvastatin hemi-calcium Form IX obtained using a synchrotron X-ray source. [0015]
  • FIG. 8 is a characteristic solid state [0016] 13C NMR spectrum of atorvastatin Form IX.
  • FIG. 9 is a characteristic powder X-ray diffraction pattern of atorvastatin hemi-calcium Form X obtained using a conventional X-ray generator with a copper anode. [0017]
  • FIG. 10 is a characteristic powder X-ray diffraction pattern of atorvastatin hemi-calcium Form X obtained using a synchrotron X-ray source. [0018]
  • FIG. 11 is a characteristic solid state [0019] 13C NMR spectrum of atorvastatin hemi-calcium Form X.
  • FIG. 12 is a characteristic powder X-ray diffraction pattern of atorvastatin hemi-calcium Form XI obtained using a conventional X-ray generator with a copper anode. [0020]
  • FIG. 13 is an overlay of typical powder X-ray diffraction patterns of atorvastatin hemi-calcium Form XII obtained using a conventional X-ray generator with a copper anode.[0021]
  • SUMMARY OF THE INVENTION
  • The present invention provides new atorvastatin hemi-calcium solvates and hydrates. [0022]
  • The present invention provides a novel crystalline form of atorvastatin hemi-calcium denominated Form VI and novel processes for its preparation. [0023]
  • In another aspect, the present invention provides a novel crystalline form of atorvastatin hemi-calcium denominated Form VIII and novel processes for its preparation. [0024]
  • In another aspect, the present invention provides a novel crystalline form of atorvastatin hemi-calcium denominated Form IX and novel processes for its preparation. [0025]
  • In another aspect, the present invention provides a novel crystalline form of atorvastatin hemi-calcium denominated Form X and novel processes for its preparation. [0026]
  • In another aspect, the present invention provides a novel crystalline form of atorvastatin hemi-calcium denominated Form XI and novel processes for its preparation. [0027]
  • In another aspect, the present invention provides a novel crystalline form of atorvastatin hemi-calcium denominated Form XII and novel processes for its preparation. [0028]
  • In another aspect, the present invention provides novel processes for preparing atorvastatin hemi-calcium Form I. [0029]
  • In another aspect, the present invention provides novel processes for preparing atorvastatin hemi-calcium Form II. [0030]
  • In another aspect, the present invention provides novel processes for preparing atorvastatin hemi-calcium Form IV. [0031]
  • In another aspect, the present invention provides novel processes for preparing atorvastatin hemi-calcium Form V. [0032]
  • In another aspect, the present invention provides novel processes for preparing amorphous atorvastatin hemi-calcium. [0033]
  • In another aspect, the invention provides compositions and dosage forms comprising atorvastatin hemi-calcium Forms VI, VII, VIII, IX, X, XI and their mixtures. [0034]
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Some crystalline forms of atorvastatin hemi-calcium of the present invention exist in a solvated state and hydrated state. Hydrates have been analyzed by Karl-Fisher and thermogravimetric analysis. [0035]
  • Powder X-ray diffraction (“PXRD”) analysis employing conventional CuK[0036] α radiation was performed by methods known in the art using a SCINTAG powder X-ray diffractometer model X'TRA equipped with a solid-state detector. Copper radiation of λ=1.5418 Å was used. Measurement range: 2-40 degrees 2θ. The sample was introduced using a round standard aluminum sample holder with round zero background quartz plate in the bottom. Powdered samples were gently ground and filled in the round cavity of the sample holder by pressing with a glass plate.
  • PXRD analysis using a synchrotron X-ray source was performed at the National Synchrotron Light Source of the Brookhaven National Laboratory (diffractometer station X3B1). Samples were loosely packed into thin-walled glass capillaries. X-ray radiation was approximately 1.15 Å. Since the wavelength of incident light does correspond to the wavelength most commonly used in conventional PXRD analysis, X-ray peak positions in the diffraction patterns obtained from the synchrotron source are expressed in terms of d spacings, which are invariant with changes in wavelength of the X-radiation used to produce the pattern. The scan width was from 1 to 20 degrees 2θ. The resolution of the spectra is in the range of 0.01 to 0.03 degrees full width at half maximum. The positions of well resolved peaks are accurate to within 0.003 to 0.01 degrees. [0037]
  • The CP/MAS [0038] 13C NMR measurements were made at 125.76 MHz and were performed on a Bruker DMX-500 digital FT NMR spectrometer equipped with a BL-4 CP/MAS probehead and a High Resolution/High Performance 1H preamplifier for solids: spin rate 5.0 kHz, pulse sequence SELTICS, sample holder: Zirconia rotor 4 mm diameter.
  • Atorvastatin hemi-calcium Form VI is characterized by a powder X-ray diffraction pattern (FIG. 1) with peaks at 3.5, 5.1, 7.7, 8.2, 8.7, 10.0, 12.5, 13.8, 16.2, 17.2, 17.9 18.3, 19.5, 20.4, 20.9, 21.7, 22.4, 23.2, 24.3, 25.5±0.2 degrees two-theta. The most characteristic peak is observed at 19.5±0.2 degrees two-theta. The PXRD pattern of Form VI was taken using a Phylips diffractometer similar to the SCINTAG instrumentation described above. [0039]
  • Atorvastatin hemi-calcium Form VI may be obtained by dissolving any other form of atorvastatin hemi-calcium, preferably Form I, in acetone and then precipitating Form VI by addition of an anti-solvent, preferably water. [0040]
  • Atorvastatin hemi-calcium Form VII is characterized by a powder X-ray diffraction pattern (FIG. 2) having two broad peaks, one in the range 18.5-21.8 and the other in the range of 21.8-25.0 degrees 2θ, and other additional broad peaks at 4.7, 7.8, 9.3, 12.0, 17.1, 18.2±0.2 degrees 2θ. Samples of Form VII may contain up to 12% water. [0041]
  • Form VII is readily distinguished from known forms of atorvastatin hemi-calcium by the broad peaks at 7.8 and 9.3±0.2, degrees 2θ. For instance, Form I has peaks at 9.2, 9.5, 10.3, 10.6, 11.0 and 12.2 degrees 2θ according to the information provided in U.S. Pat. No. 5,969,156. In this region, Form II has two sharp peaks at 8.5 and 9.0 degrees 2θ and Form IV has one strong peak at 8.0 degrees 2θ. The other broad peaks in the region of 15-25 degrees 2θ distinguish Form VII from all other forms. Forms I, III and IV all have sharp peaks in this region. [0042]
  • Atorvastatin hemi-calcium Form VII may be prepared by treating atorvastatin calcium Forms I or V with ethanol, preferably absolute ethanol, at room temperature to reflux temperature for a period of from about 1 h to about 24 h, preferably 2.5-16 h. If the process is carried out in refluxing EtOH, the conversion is complete in about 2.5 h. If the process is carried out at room temperature a longer period is required. [0043]
  • Atorvastatin hemi-calcium Form VIII is characterized by a powder X-ray diffraction pattern (FIG. 3) obtained using conventional CuK[0044] α radiation having peaks at 4.8, 5.2, 5.9, 7.0, 8.0, 9.3, 9.6, 10.4, 11.9, 16.3, 17.1(broad), 17.9, 18.6, 19.2, 20.0, 20.8, 21.1, 21.6, 22.4, 22.8, 23.9, 24.7, 25.6, 26.5, 29.0±0.2 degrees two-theta. The most characteristic peaks are at 6.9, 9.3, 9.6, 16.3, 17.1, 19.2, 20.0, 21.6, 22.4, 23,9, 24.7, 25.6, and 26.5±0.2 degrees 2θ. Samples of atorvastatin hemi-calcium Form VIII were found to contain up to 7% water by Karl Fisher. Form VIII is readily distinguished from Forms I-IV by its characteristic sharp peaks at 9.3 and 9.6 degrees 2θ. According to the information provided in U.S. Pat. No. 5,969,156, Form I has one medium peak at 6.9 and sharp peaks at 9.2, 9.5, 10.3, 10.6, 11.0 and 12.2±0.2 degrees 2θ. Form IV is said to have two peaks at 8.0 and 9.7 degrees 2θ. Form II is said to have in this region two sharp peaks at 8.5 and 9.0 degrees 2θ. Form III has in this region one strong sharp peak at 8.7 degrees 2θ according to the information provided in U.S. Pat. No. 6,121,461. The features are not observed in the Form VIII PXRD pattern. Further, there is in the PXRD pattern of Form VIII one sharp, medium intensity peak at 7.0 which is well distinguished from other peaks in the region. A comparison of the PXRD pattern of Form VIII with the patterns of Forms I-IV reveals that this feature of the Form VIII pattern is distinctive.
  • Other peaks in the Form VIII pattern that are unique to this form are the two strong and sharp peaks at 19.2 and 20.0 degrees 2θ. In this region, Form I has sharp peaks at 21.6, 22.7, 23.3 and 23.7 degrees 2 according to the information provided in the '156 patent. Form IV is said to have peaks at 18.4 and 19.6 degrees 2θ, while Form II has two main peaks at 17.0 and 20.5 and Form III has peaks at 17.7, 18.2, 18.9, 20.0 and 20.3±0.2 degrees 2θ. [0045]
  • Synchrotron X-ray powder diffraction analysis was performed on Form VIII to determine its crystal system and unit cell dimensions. Form VIII has a monoclinic unit cell with lattice dimensions: a=18.55-18.7 Å, b=5.52-5.53 Å, c=31.0-31.2 Å and angle β between the a and c axes of 97.5-99.5°. The unit cell parameters were determined using the Le Bail method. [0046]
  • The diffractogram of FIG. 4 obtained using a synchrotron X-ray source has many sharp well resolved peaks. The d-spacings of some of the more prominent peaks are listed in Table 1, along with the positions in units of two-theta that the peaks would have using CuK[0047] α radiation of 1.5418 Å.
    TABLE 1
    d (Å) a
    30.81  2.87
    18.46  4.79
    16.96  5.21
    15.39  5.74
    14.90  5.93
    12.78  6.92
    11.05  8.00
     9.58  9.23
     9.22  9.59
     7.42 11.93
     6.15 14.40
     5.43 16.32
     4.62 19.21
     4.44 20.00
     3.98 22.34
  • Because of the natural variation between independent samples and measurements, the peak positions may deviate from the reported positions by as much as 0.5% of the d values. There may be larger shifts if the material undergoes size reduction as micronization. [0048]
  • Atorvastatin hemi-calcium Form VIII produced the solid-state [0049] 13C NMR spectrum shown in FIG. 5. Form VIII is characterized by the following solid-state 13C nuclear magnetic resonance chemical shifts in ppm: 17.8, 20.0, 24.8, 25.2, 26.1, 40.3, 40.8, 41.5, 43.4, 44.1, 46.1, 70.8, 73.3, 114.1, 116.0, 119.5, 120.1, 121.8, 122.8, 126.6, 128.8, 129.2, 134.2, 135.1, 137.0, 138.3, 139.8, 159.8, 166.4, 178.8, 186.5. Form VIII is characterized by a solid-state 13C nuclear magnetic resonance having the following chemical shifts differences between the lowest ppm resonance and other resonances: 2.2, 7.0, 7.4, 8.3, 22.5, 23.0, 23.7, 25.6, 26.3, 28.3, 53.0, 55.5, 96.3, 98.2, 101.7, 102.3, 104.0, 105.0, 108.8, 111.0, 111.4, 116.4, 117.3, 119.2, 120.5, 122.0, 142.0, 148.6, 161.0 and 168.7. The chemical shifts reported for Form VIII are averaged from spectra taken of four samples of Form VIII. Characteristic parts of the pattern are found at 24-26 ppm (aliphatic range), 119-140 ppm (aromatic range) and other regions. The shift values are accurate to within ±0.1 ppm, except for the carbonyl peak at 178.8 ppm which has a fluctuation of ±0.4 ppm.
  • Atorvastatin hemi-calcium Form VIII can exist as an ethanol solvate containing up to about 3% ethanol by weight. [0050]
  • The following methods have been found suitable for generating Form VIII. This form may, however, also be accessible by empirical development and by routine modification of these procedures. [0051]
  • Atorvastatin hemi-calcium Form VIII may be obtained by slurrying atorvastatin hemi-calcium in a mixture of ethanol and water at elevated temperature, preferably about 78-80° C. The slurrying procedure may be incorporated into the last step of a process for preparing atorvastatin hemi-calcium, which typically is generation of the hemi-calcium salt from the atorvastatin free acid or lactone by treatment with a source of calcium ion. In such a combined procedure the salt is generated in a solvent system comprising ethanol and water. Conveniently, after precipitation of the atorvastatin hemi-calcium salt by an additional amount of water, the salt may be slurried in the reaction mixture for a period of several hours, preferably from about 6 to about 16 hours to obtain atorvastatin hemi-calcium Form VIII. [0052]
  • Form VIII also may be obtained starting from Form V by treating Form V with a mixture of EtOH:H[0053] 2O, preferably in the ratio of about 5:1 at an elevated temperature below reflux, preferably 78-80° C. An especially preferred EtOH:H2O mixture contains about 4% by volume water in ethanol. During the heating, atorvastatin Form V gradually dissolves and at the point of 78-80° C. turbidity, with or without seeding, is observed. At this point the suspension is immediately cooled to room temperature.
  • Form VIII may be obtained by treating atorvastatin hemi-calcium in EtOH, preferably absolute EtOH, at elevated temperature, preferably boiling EtOH. Under these conditions, the atorvastatin dissolves and reprecipitates. MeOH may be added at reflux. Added MeOH may adversely affect the yield, but may improve the chemical purity of the product. Starting materials for preparing Form VIII by this process can be crystalline forms of atorvastatin hemi-calcium, preferably Forms I and V and mixtures thereof or amorphous atorvastatin hemi-calcium. [0054]
  • The quantity of EtOH or mixture thereof with water is preferably in the range of from about 10 to about 100 ml g[0055] −1, more preferably about 20 to about 80 ml g−1.
  • We have discovered that atorvastatin hemi-calcium that contains greater than 0.1% des-fluoro atorvastatin hemi-calcium and/or greater than 1% trans atorvastatin hemi-calcium may be purified by suspending in a solution of about 96% ethanol and about 4% water at elevated temperature, preferably at reflux temperature. Typically, atorvastatin hemi-calcium is recovered with less than 0.07% contamination with des-fluoro atorvastatin hemi-calcium and less than 0.6% contamination with trans atorvastatin hemi-calcium. [0056]
  • Form VIII also may be prepared by suspending atorvastatin hemi-calcium in certain 1-butanol/water and ethanol/water mixtures for a period of time sufficient to cause the conversion of the atorvastatin hemi-calcium to Form VIII. 1-Butanol/water mixtures should contain about 20% 1-butanol by volume at elevated temperature, preferably at reflux temperature. [0057]
  • Atorvastatin hemi-calcium Form IX is characterized by a powder X-ray diffraction pattern (FIG. 5) with peaks at 4.7, 5.2, 5.7, 7.0, 7.9, 9.4, 10.2, 12.0, 17.0, 17.4, 18.2, 19.1, 19.9, 21.4, 22.5, 23.5, 24.8 (broad), 26.1, 28.7, 30.0±0.2 degrees two-theta. The most characteristic peaks of Form IX are at 6.9, 17.0, 17.4, 18.2, 18.6, 19.1, 19.9, 21.4, 22.5 and 23.5±0.2 degrees two-theta. Form IX may contain up to 7% water. Form IX also can exist as a butanol solvate containing up to about 5% butanol. [0058]
  • Form IX is readily distinguished by its characteristic sharp peaks at 18.6, 19.1, 19.9, 21.4, 22.5, 23.5 degrees 2θ. For comparison, Form I has sharp peaks at 21.6, 22.7, 23.3 and 23.7 degrees 2θ, while Form IV has in this region sharp peaks at 18.4 and 19.6 degrees 2 and Form II has two main peaks at 17.0 and 20.5 degrees 2θ, according to information in the '156 patent. Form III has in this region peaks at 17.7, 18.3, 18.9, 20.0 and 20.3 degrees 2θ. Also, there is in the PXRD pattern of Form IX, as there is in the pattern of Form VIII, a sharp, well distinguished medium intensity peak at 7.0 degrees 2θ. [0059]
  • The crystal system and unit cell dimension of Form IX were determined using synchrotron X-ray powder diffraction analysis. Form IX has a monoclinic crystal lattice with lattice dimensions: a=18.75-18.85 Å, b=5.525-5.54 Å, c=30.9-31.15 Å and angle β between the a and c axes of 96.5-97.5°. [0060]
  • The d-spacings of some of the more prominent peaks in the synchrotron X-ray powder diffractogram of FIG. 7 are listed in Table 2, along with the positions in units of two-theta that the peaks would have using CuK[0061] α radiation.
    TABLE 2
    d (Å) a
    30.86  2.86
    18.67  4.73
    16.91  5.23
    15.17  5.83
    12.66  6.98
    11.20  7.89
     9.50  9.31
     9.28  9.53
     8.63 10.25
     7.69 11.51
     7.38 11.99
     6.51 13.60
     5.45 16.26
     5.26 16.86
     5.20 17.05
     5.12 17.32
     4.87 18.22
     4.76 18.64
     4.63 19.17
     4.47 19.86
     4.14 21.46
     4.08 21.78
     3.78 23.54
     3.73 23.86
     3.62 24.59
     3.58 24.87
  • Because of the natural variation between independent samples and measurements, the peak positions may deviate from the reported positions by as much as 0.5% of the d values. There may be larger shifts if the material undergoes size reduction as micronization. [0062]
  • Atorvastatin hemi-calcium Form IX produced the solid-state [0063] 13C NMR spectrum shown in FIG. 8. Form IX is characterized by the following solid-state 13C nuclear resonance chemical shifts in ppm: 18.0, 20.4, 24.9, 26.1, 40.4, 46.4, 71.0, 73.4, 114.3, 116.0, 119.5, 120.2, 121.7, 122.8, 126.7, 128.6, 129.4, 134.3, 135.1, 136.8, 138.3, 139.4, 159.9, 166.3, 178.4, 186.6. Form IX is characterized by a solid-state 13C nuclear resonance having the following chemical shifts differences between the lowest ppm resonance and other resonances: 2.4, 6.9, 8.1, 22.4, 28.4, 53.0, 55.4, 96.3, 98.0, 101.5, 102.2, 103.7, 104.8, 108.7, 110.6, 111.4, 116.3, 117.1, 118.8, 120.3, 121.4, 141.9, 148.3, 160.4, 168.6. Characteristic parts of the pattern are found at 24-26 ppm (aliphatic range), 119-140 ppm (aromatic range) and other regions. The chemical shifts of Form IX are an average taken from spectra on two samples of Form IX. The shift values are accurate to within ±0.1 ppm.
  • Form IX may be prepared by the following processes though this form may be accessed by empirical development and by routine modification of these procedures. [0064]
  • Atorvastatin hemi-calcium Form IX may be prepared by slurrying atorvastatin hemi-calcium in butanol and isolating Form IX by, for example, filtration or decantation of the butanol, preferably by filtration. Preferred temperature ranges for the slurrying are from 78° C. to the reflux temperature of the solvent. Recovery of atorvastatin hemi-calcium salt from the slurry can be enhanced by addition of an anti-solvent to the slurry before isolating Form IX. Preferred anti-solvents include isopropanol and n-hexane. Starting materials for preparing Form IX by this process can be crystalline or amorphous atorvastatin hemi-calcium, preferably Forms I and V and mixtures thereof. [0065]
  • Form IX may be prepared by suspending Form VIII in ethanol, preferably absolute ethanol, at room temperature for a period of time sufficient to convert form VIII to Form IX, which may range from a few hours to 24 hours and typically requires about 16 hours. Thereafter Form IX is recovered from the suspension. Form IX also may be prepared by maintaining Form VIII under a humid atmosphere. [0066]
  • Form IX also may be prepared by suspending atorvastatin hemi-calcium Form V in mixtures of 1-butanol and either ethanol or water at reflux temperature for a period of time sufficient to convert Form V into Form IX and recovering Form IX from the suspension. Preferably the mixtures contain about 50 volume percent of each component. [0067]
  • Atorvastatin hemi-calcium Form X is characterized by a powder X-ray diffraction pattern (FIG. 7) having peaks at 4.8,5.3,5.9,9.6, 10.3, 11.5, 12.0, a double peak at 16.1 and 16.3, 16.9, 17.4, 18.2, 19.2, 19.4, 20.0, 20.8, 21.6, 22.0, 22.8, 23.6, 24.6, 25.0, 25.5, 26.2, 26.8, 27.4, 28.0, 30.3±0.2 degrees 2θ. The most characteristic peaks are two peaks at 20.0 and 20.8±0.2 degrees 2 and other peaks at 19.1, 19.4, 22.8, 23.6, 25.0, 28.0, 30.3±0.2 degrees 2θ. Form X contains up to 2% ethanol and may contain up to 4% water. [0068]
  • Form X is distinguished from that of Form IV by having characteristic peaks at 7.0, 19.9, 20.7, 24.1, 25.0, 28.0 and 30.3±0.2 degrees 2θ. These features are clearly distinguished from those appearing the corresponding regions of the PXRD patterns of Forms I-IV which have been previously described. [0069]
  • The crystal system and unit cell dimension of Form X were determined using synchrotron X-ray powder diffraction analysis. Form X has a monoclinic crystal lattice with lattice dimensions: a=18.55-18.65 Å, b=5.52-5.53 Å, c=30.7-30.85 Å and angle β between the a and c axes of 95.7-96.7°. [0070]
  • The d-spacings of some of the more prominent peaks in the synchrotron X-ray powder diffractogram of FIG. 10 are listed in Table 3, along with the positions in units of two-theta that the peaks would have using CuK[0071] α radiation.
    TABLE 3
    d (Å) a
    30.63  2.88
    18.49  4.78
    16.66  5.30
    15.12  5.85
    12.49  7.08
    11.19  7.90
    10.20  8.67
     9.38  9.43
     9.24  9.57
     9.13  9.69
     8.58 10.31
     7.64 11.58
     7.36 12.02
     7.26 12.19
     6.81 13.00
     6.50 13.62
     6.16 14.38
     5.91 14.99
     5.24 16.92
     5.19 17.08
     5.06 17.53
     4.86 18.25
     4.74 18.72
     4.65 19.09
     4.61 19.25
     4.56 19.47
     4.12 21.57
     4.10 21.95
     3.93 22.62
     3.90 22.80
     3.77 23.60
  • Because of the natural variation between independent samples and measurements, the peak positions may deviate from the reported positions by as much as 0.5%. There may be larger shifts if the material undergoes size reduction as micronization. [0072]
  • Atorvastatin hemi-calcium Form X produced the solid-state [0073] 13C NMR spectrum shown in FIG. 11. Form X is characterized by the following solid-state 13C nuclear resonance chemical shifts in ppm: 17.7, 18.7, 19.6, 20.6, 24.9, 43.4, 63.1, 66.2, 67.5, 71.1, 115.9, 119.5, 122.4, 126.7, 128.9, 134.5, 138.0, 159.4, 166.2, 179.3, 181.1, 184.3, 186.1. Form X is characterized by a solid-state 13C nuclear magnetic resonance having the following chemical shifts differences between the lowest ppm resonance and other resonances: 1.0, 1.9, 2.9, 7.2, 25.7, 45.4, 48.5, 49.8, 53.4, 98.2, 101.8, 104.7, 109.0, 111.2, 116.8, 120.3, 141.7, 148.5, 161.6, 163.4, 166.6, 168.4. Characteristic parts of the pattern are found at 24-26 ppm (aliphatic range), 119-140 ppm (aromatic range) and other regions. The chemical shifts of Form X are averaged from three spectra taken of three samples of Form X. The values reported are within ±0. 1 ppm, except for the carbonyl peak at 179.3 ppm that is accurate within ±0.4 ppm.
  • Atorvastatin hemi-calcium Form X may be prepared by treating crystalline atorvastatin hemi-calcium, preferably Form V or Form I or mixtures thereof, or amorphous atorvastatin hemi-calcium with a mixture of ethanol and water, preferably in a ratio of about 5:1, at elevated temperature, preferably at reflux temperature, for a period of from about half an hour to a few hours, preferably about 1 h. The starting material may be 0.15 added to the EtOH:water mixture at room temperature, followed by gradual heating of the suspension to reflux. Alternatively, the starting form of atorvastatin hemi-calcium may be added to the refluxing solvent mixture. In either case, the atorvastatin hemi-calcium should be observed to dissolve in the mixture and then reprecipitate in Form X. The ratio of atorvastatin hemi-calcium to the EtOH:water mixture preferably ranges from about 1:16 to about 1:25 (g:ml), more preferably from about 1:16 to about 1:21 (g:ml) and most preferably about 1:16 (g:ml). Form X may be collected by filtration shortly after cooling to room temperature or the suspension may be stirred for an addition period of from about 1 to about 20 hours, more preferably from about 3 to about 16 hours, before collecting the Form X. [0074]
  • Atorvastatin hemi-calcium Form XI is characterized by a powder X-ray diffraction pattern (FIG. 9) having peaks at 3.2, 3.7, 5.1, 6.3, 7.8, 8.6, 9.8, 11.2, 11.8, 12.4, 15.4, 18.7, 19.9, 20.5, 24.0±0.2 degrees two-theta. [0075]
  • Form XI may be obtained by suspending atorvastatin hemi-calcium Form V in methyl ethyl ketone (“MEK”) at room temperature for a period of time sufficient to cause the conversion of Form V into Form XI. [0076]
  • Form XI also may be obtained by preparing a gel containing atorvastatin hemi-calcium in isopropyl alcohol and then drying the gel. The gel is best prepared by saturating isopropyl alcohol with atorvastatin hemi-calcium at reflux temperature and then cooling to room temperature. Extensive stirring at room temperature, as long as or more than 20 h, may be required in order for the gel to form. In the gel state, the solution is detectably more resistant to stirring and does not pour smoothly. The gel remains flowable in the sense that it can be stirred if sufficient force is applied and would not tear under such force. [0077]
  • Atorvastatin hemi-calcium Form XII is characterized by a powder X-ray diffraction pattern having peaks at 2.7, 8.0, 8.4, 11.8, 18.2, 19.0, 19.8, 20.7±0,2 degrees two-theta, and a halo that indicates the presence of amorphous material. Typical X-ray powder diffraction patterns of atorvastatin hemi-calcium Form XII are shown in FIG. 10. [0078]
  • Form XII may be prepared directly from the following compound [0079]
    Figure US20020183378A1-20021205-C00002
  • whose systematic chemical name is [R-(R*,R*)]-2-(4-fluorphenyl)-β,δ-dioxane-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoic ester, and which will hereafter be referred to as pyrrole acetonide ester or PAE. Form XII is prepared by first subjecting PAE to conditions that cleave the acetonide and tert-butyl ester group. Prefered conditions employ aqueous hydrochloric acid, more preferably about 1.5% aqueous hydrochloric acid. The solution of atorvastatin, in either free acid or lactone form, or mixture thereof, is then treated with calcium hydroxide, preferably a modest excess thereof, more preferably about 1.5 equivalents with respect to the PAE. After association of the atorvastatin with dissolved calcium derived from the added hydroxide salt, any excess calcium hydroxide may be separated by filtration. One important feature of this process is the subsequent manipulation of the filtrate. Water is slowly added to the reaction mixture at mildly elevated temperature, preferably about 65° C., until atorvastatin hemi-calcium precipitates. At that point the temperature is increased until a clear solution is once again attained. The mixture is then allowed to cool resulting in the precipitation of atorvastatin hemi-calcium. The isolated precipitate is atorvastatin hemi-calcium Form XII. [0080]
  • The present invention also provides novel processes for preparing known forms of atorvastatin hemi-calcium. [0081]
  • Form I may be obtained by treating any form of atorvastatin hemi-calcium with water at room temperature to 100° C. for a period between a few to about 25 hours, preferably about 16 hours. Preferred starting materials are Forms V, VII, VIII, IX and X of atorvastatin hemi-calcium. [0082]
  • Form I also may be prepared by sonicating a suspension of atorvastatin hemi-calcium in ethanol, preferably absolute ethanol or in water, at between room temperature and the reflux temperature of the solvent for a period of a few minutes. Preferably between 1 and 3 minutes. Atorvastatin hemi-calcium Form VII is a preferred starting material though other forms may be used as well. [0083]
  • Form II may be prepared directly from [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dioxane-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoic ester (PAE) according to Example 31. [0084]
  • Atorvastatin hemi-calcium Form IV may be prepared by suspending Form I or Form V in 1-butanol for a period of time sufficient to complete the conversion of Form I or Form V to Form IV and then isolating Form IV from the mixture. The conversion may require a prolonged period depending on temperature and other conditions. The conversion typically takes about 24-72 hours at room temperature. [0085]
  • Form IV also may be obtained by suspending Form V in EtOH/H[0086] 2O at 50° C. for a period of time sufficient to cause the conversion of Form V to Form IV and then recovering Form IV from the suspensions. Prefered EtOH/H2O mixtures contain about 15% H2O.
  • Form IV also may be obtained by suspending atorvastatin hemi-calcium Form V in methanol for a period of time sufficient to cause the conversion of Form V to Form IV. The rate of conversion is sensitive to temperature and may take from about 1 to about 25 hours under typical laboratory conditions. The conversion requires about 16 hours, at room temperature. The conversion may be conducted at elevated temperature up to the reflux temperature of the solvent. [0087]
  • Form V may be prepared from PAE according to the process described with reference to the preparation of atorvastatin hemi-calcium Form XII. Form V may be obtained by drying Form XII at about 65° C. for about 24 hours. The atorvastatin hemi-calcium Form V obtained in this manner is of high purity. However, it may be further purified by suspending in a mixture of about 10% water and about 90% ethanol and re. [0088]
  • Amorphous atorvastatin hemi-calcium may be prepared by treating any other form of atorvastatin hemi-calcium with acetone at room temperature to reflux temperature for between a few hours and 25 hours, preferably about 16 hours. A preferred starting material is Form V. [0089]
  • Amorphous atorvastatin hemi-calcium also may be prepared by sonicating any form of atorvastatin hemi-calcium in acetonitrile at any temperature between room temperature and the reflux temperature of acetonitrile. Sonicating for a few minutes, preferably from 1 to 3 minutes, is sufficient to transform the starting material into amorphous atorvastatin hemi-calcium. Preferred starting forms of atorvastatin hemi-calcium are Forms VII and I. [0090]
  • Amorphous atorvastatin hemi-calcium also may be prepared by ball milling of any crystalline form of atorvastatin hemi-calcium. [0091]
  • A further aspect of the present invention is a pharmaceutical composition and dosage form containing the novel forms of atorvastatin hemi-calcium. [0092]
  • The compositions of the invention include powders, granulates, aggregates and other solid compositions comprising novel Forms VI, VII, VIII, IX, X, XI and XII of atorvastatin hemi-calcium. In addition, Forms VI, VII, VIII, IX, X, XI and XII solid compositions that are contemplated by the present invention may further include diluents, such as cellulose-derived materials like powdered cellulose, microcrystalline cellulose, microfine cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose salts and other substituted and unsubstituted celluloses; starch; pregelatinized starch; inorganic diluents like calcium carbonate and calcium diphosphate and other diluents known to the pharmaceutical industry. Yet other suitable diluents include waxes, sugars and sugar alcohols like mannitol and sorbitol, acrylate polymers and copolymers, as well as pectin, dextrin and gelatin. [0093]
  • Further excipients that are within the contemplation of the present invention include binders, such as acacia gum, pregelatinized starch, sodium alginate, glucose and other binders used in wet and dry granulation and direct compression tableting processes. Excipients that also may be present in a solid composition of Forms VI, VII, VIII, IX, X, XI and XII atorvastatin hemi-calcium further include disintegrants like sodium starch glycolate, crospovidone, low-substituted hydroxypropyl cellulose and others. In addition, excipients may include tableting lubricants like magnesium and calcium stearate and sodium stearyl fumarate; flavorings; sweeteners; preservatives; pharmaceutically acceptable dyes and glidants such as silicon dioxide. [0094]
  • The dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant and ophthalmic administration. Although the most suitable route in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral. The Dosages may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy. [0095]
  • Dosage forms include solid dosage forms, like tablets, powders, capsules, suppositories, sachets, troches and losenges as well as liquid suspensions and elixirs. While the description is not intended to be limiting, the invention is also not intended to pertain to true solutions of atorvastatin hemi-calcium whereupon the properties that distinguish the solid forms of atorvastatin hemi-calcium are lost. However, the use of the novel forms to prepare such solutions (e.g. so as to deliver, in addition to atorvastatin, a solvate to said solution in a certain ratio with a solvate) is considered to be within the contemplation of the invention. [0096]
  • Capsule dosages, of course, will contain the solid composition within a capsule which may be made of gelatin or other conventional encapsulating material. Tablets and powders may be coated. Tablets and powders may be coated with an enteric coating. The enteric coated powder forms may have coatings comprising phthalic acid cellulose acetate, hydroxypropylmethyl-cellulose phthalate, polyvinyl alcohol phthalate, carboxymethylethylcellulose, a copolymer of styrene and maleic acid, a copolymer of methacrylic acid and methyl methacrylate, and like materials, and if desired, they may be employed with suitable plasticizers and/or extending agents. A coated tablet may have a coating on the surface of the tablet or may be a tablet comprising a powder or granules with an enteric-coating. [0097]
  • Preferred unit dosages of the pharmaceutical compositions of this invention typically contain from 0.5 to 100 mg of the novel atorvastatin hemi-calcium Forms VI, VII, VIII, IX, X, XI and XII or mixtures thereof with each other or other forms of atorvastatin hemi-calcium. More usually, the combined weight of the atorvastatin hemi-calcium forms of a unit dosage are from 2.5 mg. to 80 mg. [0098]
  • Having thus described the various aspects of the present invention, the following examples are provided to illustrate specific embodiments of the present invention. They are not intended to be limiting in any way. [0099]
  • EXAMPLES General
  • Absolute ethanol containing less than 0.2% water was purchased from Biolab®. Other reagents were reagent grade and were used as received. [0100]
  • Ball milling was performed using a Retsch centrifugal ball-mill S-100 equipped with a 250 ml stainless steal milling chamber and twenty seven 10 mm diameter stainless steal balls as milling media. [0101]
  • Preparation of Atorvastatin Hemi-Calcium Form VI Example 1
  • Atorvastatin hemi-calcium Form I (1 g) was dissolved in acetone (9 ml) at room temperature and stirred for 2.5 hours. Then, water (8.5 ml) was added to get a precipitation and the mixture was then stirred for another 2.5 hours. The white solid was then filtered and dried at 50° C. for 5 hrs to obtain atorvastatin hemi-calcium Form VI (0.88 g, 88%). [0102]
  • Preparation of Atorvastatin Hemi-Calcium Form VII Example 2
  • Atorvastatin hemi-calcium Form V (1.00 g) was stirred in absolute EtOH (400 ml) at room temperature for 16 h. The solid was collected by filtration and dried at 65° C. for 24 h to give atorvastatin hemi-calcium Form VII (40 mg, 40%). [0103]
  • Example 3
  • Atorvastatin hemi-calcium Form 1 (75 mg) was stirred in absolute EtOH (30 ml) at room temperature for 16 h. The solid was collected by filtration and dried at 65° C. for 24 h to give atorvastatin hemi-calcium Form VII (0.60 g, 80%). [0104]
  • Preparation of Atorvastatin Hemi-Calcium Form VIII Example 4
  • To a flask equipped with a magnetic stirrer 1.0 g (1.59×10[0105] −3 mole) of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dioxane-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoic ester were put in suspension in a 90% aqueous solution of acetic acid (10 ml). The reaction mixture was heated to 50° C. for three hours and then stirred at room temperature until the reaction was complete as determined by HPLC. The solvent was evaporated and the traces of acetic acid were removed by azeotropic distillation with toluene (3×100 ml) to obtain an oil with some toluene. This oil was dissolved in EtOH (10 ml) and water (2 ml).
  • Then 5.5 eq (8.4×10[0106] −3 mole, 622 mg) of Ca(OH)2 and tetrabutyl ammonium bromide (5%, 0.05 g) were added. The reaction mixture was heated at 50° C. for 5 hours until the reaction was complete according to HPLC. Then a hot filtration was done under vacuum to remove the excess of Ca(OH)2. The reaction mixture was then cooled to room temperature. To this solution water (50 ml) was added while stirring. The white precipitate was stirred at RT overnight, filtered under vacuum and dried at 65° C. for 18 hours to give 145 mg (16%) of atorvastatin hemi-calcium salt Form VIII.
  • Example 5
  • Atorvastatin hemi-calcium Form I (1 g) was slurried in absolute EtOH (80 ml), under reflux, for 24 hrs. The white solid was then filtered and dried at 65° C. for 20 hrs to obtain atorvastatin hemi-calcium Form VIII (0.85 g, 85%). [0107]
  • Example 6
  • Atorvastatin hemi-calcium Form I (1 g) was poured in boiling absolute EtOH (40 ml). The compound began first to get soluble and then precipitate again. To this mixture was added MeOH (20 ml). The white solid was then filtered and dried at 50° C. for 20 hrs in a vacuum oven to obtain atorvastatin hemi-calcium Form VIII (188 mg, 19%). [0108]
  • Example 7
  • A suspension of 1.0 g of Atorvastatin hemi-calcium salt Form V in 1-Butanol (4 ml) and H[0109] 2O (16 ml) was heated to reflux temperature for 1 hr. The mixture was then cooled to room temperature and stirred at this temperature for additional 16 hrs. The solid was filtered and dried at 50° C. in a vacuum oven for 16 hrs to give 0.9 g (91%) of Atorvastatin hemi-calcium salt Form VIII.
  • Example 8
  • 5.0 g of Atorvastatin hemi-calcium salt Form V were added to a boiled solution of Ethanol 96% (150 ml). The mixture was refluxed for 2.5 hrs. Then it was cooled to 20° C. during 1.5 hrs, and stirred at this temperature for additional 16 hrs. The solid was filtered, washed with Ethanol 96% (2×25 ml) and dried at 65° C. for 20 hrs to give 4.4 g (88%) of Atorvastatin hemi-calcium salt Form VIII. During this process chemical purification occurs, so this process is good also for purification. [0110]
  • Example 9
  • 5.0 g of Atorvastatin hemi calcium salt Form V, with a level of 0.12% of Des-fluoro Atorvastatin, were added to a boiled solution of Ethanol 96% (150 ml). The mixture was refluxed for 2.5 hrs. Then it was cooled to 20° C. during 1.5 hrs and stirred at this temperature for additional 16 hrs. The solid was filtered, washed with Ethanol 96% (2×25 ml) and dried at 65° C. for 20 hrs to give 4.4 g (88%) of Atorvastatin hemi calcium salt with a level of 0.06% of Des-fluoro Atorvastatin. Atorvastatin is obtained in Form VIII by this procedure. [0111]
  • Example 10
  • Atorvastatin hemi-calcium Form V (5 g) in absolute EtOH (35 ml) was refluxed for 2.5 h. The reaction mixture was then cooled to room temperature and stirred for an additional 16 h. Absolute ethanol (15 ml) was then added and the suspension was filtered and the collected solids were dried at 65° C. for 20 h to yield atorvastatin hemi-calcium Form VIII (4.7 g, 94%). [0112]
  • Preparation of Atorvastatin Hemi-Calcium Form IX Example 11
  • Atorvastatin hemi-calcium Form I (1 g) was slurried in 1-butanol (20 ml) under reflux for 30 minutes. The mixture was then cooled to room temperature. The white solid was then filtered and dried at 50° C. under vacuum for 20 hrs to yield atorvastatin hemi-calcium Form IX (0.94 g, 94%). KF=0.9. [0113]
  • Example 12
  • Atorvastatin hemi-calcium Form I (1 g) was slurried in 1-butanol (20 ml) under reflux for 30 minute. Then n-hexane (40 ml) was added for further precipitation and the reaction mixture was stirred at room temperature for 2 hours. The white solid was then filtered and dried at 50° C. in a vacuum oven for 20 hrs to yield atorvastatin Form IX (0.96 g, 96%). [0114]
  • Example 13
  • Atorvastatin hemi-calcium Form I (1 g) was slurried in 1-butanol (20 ml) under reflux for 30 minute. Then, IPA (40 ml) was added for further precipitation and the reaction mixture was stirred at room temperature for 2 hours. The white solid was then filtered and dried at 50° C. for 20 hrs in a vacuum oven to yield atorvastatin hemi-calcium Form IX (0.94 g, 94%) containing 0.9% water by Karl Fisher analysis. [0115]
  • Example 14
  • Atorvastatin hemi-calcium Form VIII (800 mg) was stirred in absolute EtOH (320 ml) at room temperature for 16 h. The solid was collected by filtration and dried at 65° C. for 24 hours to give atorvastatin hemi-calcium Form IX (630 mg, 79%). [0116]
  • Example 15
  • A mixture of atorvastatin hemi-calcium Form V (2.00 g) and 1-butanol (40 ml) was refluxed at 118° C. for half an hour. The mixture was then cooled to room temperature and stirred for an additional 3 hours. The solid was then collected by filtration and dried at 65° C. for 24 hours to give atorvastatin hemi-calcium Form IX (1.83 g, 92%). [0117]
  • Example 16
  • Atorvastatin hemi-calcium Form VIII was stored under 100% relative humidity at room temperature for nine days. The resulting solid was identified as Form IX by powder X-ray diffraction analysis. [0118]
  • Example 17
  • 1 g of Atorvastatin hemi-calcium salt form V in 1-BuOH (10 ml) and H[0119] 2O (10 ml) was heated to reflux for 1 h. The mixture was then cooled to room temperature and stirred at this temperature for additional 16 hrs. Filtration and drying at 65° C. for 24 hrs gave 0.79 g (79%) of Atorvastatin hemi-calcium salt form IX.
  • Example 18
  • 1 g of Atorvastatin hemi-calcium salt form V in 1-BuOH (10 ml) and EtOH (10 ml) was heated to reflux for 1 h. The mixture was then cooled to room temperature and stirred at this temperature for additional 16 hrs. Filtration and drying at 65° C. for 24 hrs gave 0.98 g (98%) of Atorvastatin. hemi-calcium salt form IX. [0120]
  • Preparation of Atorvastatin Hemi-Calcium Form X Example 19
  • Atorvastatin hemi-calcium Form V (10.00 g) was suspended in a mixture of EtOH (135 ml) and water (24 ml) and heated to reflux for 1 h. The mixture was then cooled to room temperature and stirred for an addition 16 h. The solid was collected by filtration and dried at 65° C. for 24 h to give atorvastatin hemi-calcium Form X (8.26 g, 83%). [0121]
  • Example 20
  • Atorvastatin hemi-calcium Form V (1.00 g) in a mixture of EtOH (9 ml) and water (1.6 ml) was refluxed for 1 h. The mixture was cooled to room temperature and then stirred an additional 3 h. The solid was collected by filtration and dried at 65° C. for 24 h to give atorvastatin hemi-calcium Form X (0.80 g, 80%). [0122]
  • Preparation of Atorvastatin Hemi-Calcium Form XI Example 21
  • 1.0 g of Atorvastatin hemi-calcium salt Form V was stirred in Methylethyl ketone (“MEK”) (5 ml) at room temperature for 24 hrs. The solid was then filtered, washed with MEK (2 ml) and dried at 65° C. for 20 hrs to give 0.5 g (50%) of Atorvastatin hemi-calcium salt Form XI. [0123]
  • Example 22
  • A suspension of 1.0 g of Atorvastatin hemi-calcium salt Form V in Iso-propyl alcohol (“IPA”) (7 ml) was heated to reflux temperature for 1 hr. The mixture was then cooled to room temperature and stirred at this temperature for additional 20 hrs. A gelatinous product was obtained. After addition of IPA (3 ml) the gel was filtered and dried at 65° C. for 20 hrs to give 0.8 g (80%) of Atorvastatin hemi-calcium salt Form XI. [0124]
  • Preparation of Atorvastatin Hemi-Calcium Form XII Example 23
  • To a cylindrical reactor equipped with a distillation apparatus and a mechanical stirrer, 20 g (30.6 mmole) of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dioxane-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoic ester (=pyrrole acetonide ester=PAE) were put in suspension in 250 ml of absolute Ethanol and 50 ml of aqueous 1.5% Hydrochloric acid. The reaction mixture was heated to 40° C. for 9-11 hrs, while a continuous distillation of a mixture of Ethanol, Acetone and water, under reduced pressure (500-600 mbar), was performed. Make-up of absolute Ethanol was done every hour (35-40 ml.). After 9-11 hours there was a reduction in the level of PAE to below 0.1% (according to HPLC). Without any further treatment, Ca(OH)[0125] 2 (1.5 eq., 3.4 g) were added. The reaction mixture was heated to 70° C. for 4-5 hrs. Then the excess of Ca(OH)2 was collected by filtration. To the hot filtrate (65° C.), 350 ml of water were added slowly (using a dosing pump) during ¾-1 hour at 65° C. During the addition of water Atorvastatin hemi-calcium salt precipitated. After the addition of water the reaction mixture was heated to reflux (84° C.) till a clear solution was obtained. Then the mixture was cooled to 20° C. during 3 hrs and was stirred at this temperature for an additional 12-16 hrs. The solid was then filtered to give 45.0 g of wet cake of Atorvastatin hemi-calcium salt crystal form XII.
  • Preparation of Known Atorvastatin Hemi-Calcium Form I Example 24
  • Atorvastatin hemi-calcium Form V (1.00 g) was stirred in water (400 ml) at room temperature for 16 h. The solid was collected by filtration and dried at 65° C. for 24 hours to yield atorvastatin hemi-calcium Form 1 (0.7 g, 70%). [0126]
  • Example 25
  • A mixture of atorvastatin hemi-calcium Form VII (10.00 g) in water (100 ml) was refluxed for 2 h. The mixture was cooled to room temperature and stirred for an additional hour. The solid was collected by filtration and dried at 65° C. for 24 h to yield atorvastatin hemi-calcium Form 1 (9.64 g, 96%). [0127]
  • Example 26
  • Atorvastatin hemi-calcium Form VIII (800 mg) was stirred in water (320 ml) at room temperature for 16 h. The solid was collected by filtration and dried at 65° C. for 24 h to yield atorvastatin hemi-calcium Form 1 (350 mg, 44%). [0128]
  • Example 27
  • Atorvastatin hemi-calcium Form X (1.0 g) was stirred in water (400 ml) at room temperature for 24 h. The solid was collected by filtration and dried at 65° C. for 24 h to yield atorvastatin hemi-calcium Form 1 (720 mg, 72%). [0129]
  • Example 28
  • Atorvastatin hemi-calcium Form IX (750 mg) was stirred in water (300 ml) at room temperature for 24 h. The solid was collected and dried at 65° C. for 20 h to give atorvastatin calcium Form 1 (420 mg, 56%). [0130]
  • Example 29
  • Atorvastatin hemi-calcium Form VII (1.00 g) was stirred in absolute EtOH (20 ml) at room temperature. The slurry was then placed into a sonicator for 1.5 min (energy=235 kJ, Amp.=50%) to obtain a clear solution. After addition of water (14 ml), a precipitate formed and the slurry was put in the sonicator for another 2 min. (energy=3.16 kJ, Amp.=50%) which caused the slurry to gel The gel was dried at 65° C. for 20 h to give atorvastatin hemi-calcium Form 1 (0.50 g, 50%). [0131]
  • Example 30
  • Atorvastatin hemi-calcium Form VII (1.00 g) was stirred in water (200 ml) at room temperature. The slurry was then placed into a sonicator for 2 min. (energy=3.0 kJ, Amp.=50%) which caused the slurry to gel. The gel was dried at 65° C. for 20 h to yield atorvastatin hemi-calcium Form 1 (0.92 g, 92%). [0132]
  • Preparation of Known Atorvastatin Hemi-Calcium Form II Example 31
  • To a cylindrical reactor equipped with a distillation apparatus and a mechanical stirrer, 20 g (30.6 mmole) of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dioxane-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoic ester (=pyrrole acetonide ester=PAE) were put in suspension in 135 ml of Methanol and 7.6 ml of aqueous 10% Hydrochloric acid. The reaction mixture was heated to 35° C. for 3 hrs, while a continuous distillation of a mixture of Methanol, Acetone and water under reduced pressure (820 mbar) was performed. Make-up of Methanol was done every ½ hour (35 ml). After 3 hrs the level of PAE reduced below 0.1% (according to HPLC). Without any further treatment, Ca(OH)[0133] 2 (1.5 eq., 3.4 g), water (5 ml) and Methanol (45 ml) were added. The reaction mixture was heated to 70° C. for 2 hrs. Then the excess of Ca(OH)2 was collected by filtration and the Ca(OH)2 cake was washed with Methanol (2×10 ml). To the filtrate, 300 ml of water were added slowly (using a dosing pump) during ¾ hour at 65° C. During the addition of water Atorvastatin hemi-calcium salt precipitated. After the addition of water the reaction mixture was heated to reflux temperature (78° C.) for 1 hour. Then the mixture was cooled to 20° C. during 3 hrs and was stirred at this temperature for additional 20 hrs. The solid was then filtered and dried at 65° C. for 48 hrs to give 16.9 g (96%) Atorvastatin hemi-calcium salt crystal form II.
  • KF=3.2% [0134]
  • Preparation of Known Atorvastatin Hemi-Calcium Form IV Example 32
  • Atorvastatin hemi-calcium salt Form I (1.0 g) was stirred in 9 ml of 1-butanol at room temperature for 24 hours. The white solid was then filtered and dried at 50° C. in a vacuum oven for 16 hours to obtain 0.83 g (83%) of atorvastatin hemi-calcium salt Form IV. [0135]
  • Example 33
  • Atorvastatin hemi-calcium salt Form V (1.0 g) was stirred in 20 ml of 1-butanol at room temperature for 72 hours. The white solid was then filtered and dried at 65° C. in an oven for 20 hours to obtain 0.82 g (82%) of atorvastatin hemi-calcium salt Form IV. [0136]
  • Example 34
  • Atorvastatin hemi-calcium salt form V (2.0 g) was stirred in a mixture of EtOH (18 ml) and water (3.2 ml) at 50° C. for 1 hour. The precipitate was then filtered and dried at 65° C. for 20 hours to obtain 1.60 g (80%) of atorvastatin hemi-calcium salt form IV. [0137]
  • Example 35
  • A mixture of atorvastatin hemi-calcium Form V (2.00 g) and methanol (20 ml) was refluxed for 1 hour. The mixture was cooled to room temperature and stirred for an additional 16 hours. The solid was collected by filtration and dried at 65° C. for 24 to give atorvastatin calcium Form IV (1.37 g, 56%). [0138]
  • Example 36
  • A mixture of atorvastatin hemi-calcium Form V (1.00 g) in methanol (10 ml) was stirred at room temperature for 20 hours. The solid was collected by filtration and dried at 65° C. for 24 hours to give atorvastatin hemi-calcium Form IV (0.25 g, 25%). [0139]
  • Preparation of Atorvastatin Hemi-Calcium Form V Example 37
  • To a cylindrical reactor equipped with a distillation apparatus and a mechanical stirrer, 20 g (30.6 mmole) of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dioxane-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoic ester (=pyrrole acetonide ester=PAE) were put in suspension in 250 ml of absolute Ethanol and 50 ml of aqueous 1.5% Hydrochloric acid. The reaction mixture was heated to 40° C. for 9-11 hrs, while a continuous distillation of a mixture of Ethanol, Acetone and water, under reduced pressure (500-600 mbar), was performed. Make-up of absolute Ethanol was done every hour (35-40 ml.). After 9-11 hours there was a reduction in the level of PAE to below 0.1% (according to HPLC). Without any further treatment, Ca(OH)[0140] 2 (1.5 eq., 3.4 g) were added. The reaction mixture was heated to 70° C. for 4-5 hrs. Then the excess of Ca(OH)2 was collected by filtration. To the hot filtrate (65° C.), 350 ml of water were added slowly (using a dosing pump) during ¾-1 hour at 65° C. During the addition of water Atorvastatin hemi-calcium salt precipitated. After the addition of water the reaction mixture was heated to reflux (84° C.) till a clear solution was obtained. Then the mixture was cooled to 20° C. during 3 hrs and was stirred at this temperature for an additional 20 hrs. The solid was then filtered to give 45.0 g of wet cake of Atorvastatin hemi-calcium salt crystal form XII. This solid was dried at 65° C. for 24 hrs to give 16.7 g (95%) Atorvastatin hemi-calcium salt crystal form V.
  • KF2.8%-6.6%. [0141]
  • Process for Purifying Atorvastatin Hemi-calcium Form V Example 38
  • 5.0 g of Atorvastatin hemi-calcium salt Form V were added to a boiled aqueous solution of Ethanol 90% (150 ml). The mixture was refluxed for 2.5 hrs. Then it was cooled to 20° C. during 1.5 hrs and stirred at this temperature for additional 16 hrs. The solid was then filtered, washed with Ethanol 90% (2×25 ml) and dried at 65° C. for 20 hrs to give 3.4 g (68%) of Atorvastatin hemi-calcium salt Form V. [0142]
  • Preparation of Known Amorphous Atorvastatin Hemi-calcium Example 39
  • Atorvastatin hemi-calcium Form V (2.00 g) was stirred in acetone (14 ml) at room temperature in a closed flask for 16 h. After 2 hours, the mixture clarified. While continuing to stir at room temperature, a solid precipitated. The acetone was decanted and the solid was collected with a spatula and transferred to a drying oven and dried at 65° C. for 20 h to give amorphous atorvastatin hemi-calcium (1.85 g, 93%). [0143]
  • Example 40
  • Atorvastatin hemi-calcium Form VII (1.00 g) was stirred in acetonitrile (20 ml) at room temperature. The slurry was then sonicated for 2 min. (energy =2.5 kJ, Amp. =50%). After decantation the acetonitrile, the solid was dried at 65° C. for 20 h to give amorphous atorvastatin hemi-calcium (0.71 g, 71%). [0144]
  • Example 41
  • Atorvastatin hemi-calcium Form I (1.00 g) was stirred in acetonitrile (20 ml) at room temperature. The slurry was then placed into a sonicator for 2 min. (energy=2.5 kJ, Amp.=50%). After decanting the acetonitrile, the solid was dried at 65° C. for 20 h to give amorphous atorvastatin hemi-calcium (0.71 g, 71%). [0145]
  • Example 42
  • Atorvastatin hemi-calcium (108 g) and twenty seven 10 mm diameter stainless steel milling balls were loaded into the milling chamber of the ball mill. The chamber was weighed and the mill was balanced according to the weight. The mill was operated at 500 rpm with the mill's reversing system on for 0.5 hr. The build-up material was scraped from the chamber walls into the bulk, and the mill was again operated for 4 hr, with cleaning of build-up every 15 min. finally, the material was separated from the balls by sieving with 300 μm screen. The resulting material was analyzed by PXRD and found to be amorphous. The process was repeated using atorvastatin Forms I, V and VIII and in each instance amorphous atorvastatin hemi-calcium was obtained. [0146]
  • Having thus described the invention with reference to particular preferred embodiments and illustrated it with examples, those in the art may appreciate modifications to the invention as described and illustrated that do not depart from the spirit and scope of the invention as defined by the claims which follow. [0147]

Claims (146)

We claim:
1. Atorvastatin hemi-calcium Form VI and solvates thereof having a powder X-ray diffraction pattern substantially as depicted in FIG. 1.
2. The atorvastatin hemi-calcium Form VI and solvates thereof of claim 1 characterized by a powder X-ray diffraction pattern having peaks at 8.7, 10.0, 12.5, 17.9, 19.5, 20.9, 22.4±0.2 degrees 2θ.
3. The atorvastatin hemi-calcium Form VI and solvates thereof of claim 2 further characterized by having peaks at 7.7, 8.2, 13.8, 20.4, 21.7, 23.2, 25.5±0.2 degrees 2 in its powder X-ray diffraction pattern.
4. The atorvastatin hemi-calcium Form VI and solvates thereof of claim 2 having a narrow particle size distribution.
5. The atorvastatin hemi-calcium Form VI and solvates thereof of claim 4 wherein all of the particles are 100 microns or less in diameter.
6. The atorvastatin hemi-calcium Form VI and solvates thereof of claim 5 wherein all of the particles are 50 microns or less in diameter.
7. A process for preparing atorvastatin hemi-calcium Form VI comprising the steps of:
a) solubilizing any other crystalline or amorphous form of atorvastatin hemi-calcium in acetone,
b) precipitating atorvastatin hemi-calcium Form VI by addition of an anti-solvent, and
c) separating the solid crystalline Form VI.
8. Atorvastatin hemi-calcium Form VIII and hydrates thereof having a powder X-ray diffraction pattern substantially as depicted in FIG. 3.
9. The atorvastatin hemi-calcium Form VIII and hydrates thereof of claim 8 characterized by a powder X-ray diffraction pattern having peaks at 9.3, 9.6, 16.3, 19.2, 20.0, 21.6, 22.4, 23.9±0.2 degrees two-theta.
10. The atorvastatin hemi-calcium Form VIII and hydrates thereof of claim 9 further characterized by having peaks at 17.1 (broad), 24.7, 25.6, 26.5±0.2 degrees two-theta in its powder X-ray diffraction pattern.
11. The atorvastatin hemi-calcium Form VIII and hydrates thereof of claim 8 having a narrow particle size distribution.
12. The atorvastatin hemi-calcium Form VIII and hydrates thereof of claim 11 wherein all of the particles are 100 microns or less in diameter.
13. The atorvastatin hemi-calcium Form VIII and hydrates thereof of claim 12 wherein all of the particles are 50 microns or less in diameter.
14. The atorvastatin hemi-calcium Form VIII and hydrates thereof of claim 8 having a water content of up to 7%.
15. The atorvastatin hemi-calcium Form VIII and hydrates thereof of claim 8 that is a trihydrate.
16. The atorvastatin hemi-calcium Form VIII and hydrates thereof of claim 8 containing up to about four moles of water.
17. The atorvastatin hemi-calcium Form VIII of claim 8 containing up to about 3% ethanol.
18. Atorvastatin hemi-calcium Form VIII and hydrates thereof with d-spacings of about 30.81, 18.46, 16.96, 15.39, 14.90, 12.78, 11.05, 9.58, 9.22, 7.42, 6.15, 5.43, 4.62, 4.44, and 3.98 angstroms.
19. The atorvastatin hemi-calcium Form VIII and hydrates thereof of claim 18 that produce a high resolution X-ray powder diffraction pattern substantially as shown in FIG. 4 when irradiated with X-rays with a wavelength of about 1.15 angstroms.
20. The atorvastatin hemi-calcium Form VIII and hydrates thereof of claim 18 having monoclinic unit cell with the following unit cell parameters: a=18.55-18.7 Å, b=5.52-5.53 Å, c=31.0-31.2 Å and β=97.5-99.5.
21. Atorvastatin hemi-calcium Form VIII and hydrates thereof having a solid-state 13C nuclear magnetic resonance spectrum substantially as depicted in FIG. 5.
22. The atorvastatin hemi-calcium Form VIII and hydrates thereof of claim 21 further characterized by solid-state 13C nuclear magnetic resonances at 24.8, 25.2, 26.1, 119.5, 120.1, 121.8, 122.8, 126.6, 128.8, 129.2, 134.2, 135.1, 137.0, 138.3 and 139.8 parts per million.
23. The atorvastatin hemi-calcium Form VIII and hydrates thereof of claim 22 characterized by solid-state 13C nuclear magnetic resonances at 17.8, 20.0, 24.8, 25.2, 26.1, 40.3, 40.8, 41.5, 43.4, 44.1, 46.1, 70.8, 73.3, 114.1, 116.0, 119.5, 120.1, 121.8, 122.8, 126.6, 128.8, 129.2, 134.2, 135.1, 137.0, 138.3, 139.8, 159.8, 166.4, 178.8 and 186.5 parts per million.
24. The atorvastatin hemi-calcium Form VIII and hydrates thereof of claim 21 having the following chemical shift differences between the lowest resonance and other resonances: 2.2, 7.0, 7.4, 8.3, 22.5, 23.0, 23.7, 25.6, 26.3, 28.3, 53.0, 55.5, 96.3, 98.2, 101.7, 102.3, 104.0, 105.0, 108.8, 111.0, 111.4, 116.4, 117.3, 119.2, 120.5, 122.0, 142.0, 148.6, 161.0 and 168.7 parts per million.
25. Atorvastatin hemi-calcium Form VIII ethanolate.
26. The atorvastatin hemi-calcium ethanolate of claim 25 containing up to about 3% ethanol.
27. A process for preparing atorvastatin hemi-calcium Form VIII comprising the steps of:
a) suspending atorvastatin hemi-calcium in a mixture of ethanol and water for a period of time sufficient to convert Form V into Form VIII and
b) recovering Form VIII from the suspension.
28. The process of claim 27 wherein the mixture is a mixture of at least about 19 volumes of ethanol to about 1 volume of water.
29. The process of claim 27 wherein the temperature of the suspension is raised to 78-80° C. before Form VIII is recovered from the suspension.
30. A process for preparing atorvastatin hemi-calcium Form VIII from atorvastatin comprising the steps of:
a) converting the atorvastatin into atorvastatin hemi-calcium by contacting the atorvastatin with a source of calcium ion,
b) suspending the atorvastatin hemi-calcium in a mixture of ethanol and water for a period of time sufficient to convert the atorvastatin hemi-calcium into Form VIII, and
c) recovering Form VIII from the suspension.
31. The process of claim 30 wherein the mixture is a mixture of ethanol and water in a volume ratio of about 5:1.
32. The process of claim 30 wherein additional water is added to the suspension of atorvastatin hemi-calcium before recovering Form VIII in order to increase the recovery of Form VIII from the suspension.
33. The process of claim 30 wherein the temperature of the suspension is elevated before recovering Form VIII from the suspension.
34. The process of claim 33 wherein the elevated temperature is about 78-80° C.
35. A process for preparing atorvastatin hemi-calcium containing less than 0.1% des-fluoro atorvastatin hemi-calcium comprising suspending atorvastatin hemi-calcium that contains greater than 0.1% des-fluoro atorvastatin hemi-calcium in a mixture of about 96% ethanol and about 4% water and recovering atorvastatin hemi-calcium containing less than 0.1% des-fluoro atorvastatin hemi-calcium.
36. The process for preparing atorvastatin hemi-calcium of claim 35 wherein the atorvastatin is recovered containing less than 0.07% des-fluoro atorvastatin
37. A process for preparing atorvastatin hemi-calcium containing less than 1% trans atorvastatin hemi-calcium comprising suspending atorvastatin hemi-calcium that contains greater than 1% trans atorvastatin hemi-calcium in a mixture of about 96% ethanol and about 4% water and recovering atorvastatin hemi-calcium containing less than 1% trans atorvastatin hemi-calcium
38. The process for preparing atorvastatin hemi-calcium of claim 37 wherein the atorvastatin hemi-calcium is recovered containing less than 0.6% trans atorvastatin hemi-calcium.
39. A process for preparing atorvastatin hemi-calcium Form VIII comprising the steps of:
a) suspending atorvastatin hemi-calcium Form V in a mixture of water and a lower alcohol selected from the group consisting of 1-butanol and ethanol for a period of time to cause the conversion of Form V to Form VIII, and
b) recovering atorvastatin hemi-calcium Form VIII from the mixture.
40. The process of claim 39 wherein the mixture contains about 20% 1-butanol by volume.
41. The process of claim 39 wherein the lower alcohol is ethanol and the mixture contains about 4% water.
42. A process for preparing atorvastatin hemi-calcium Form VIII comprising the steps of:
a) suspending atorvastatin hemi-calcium in ethanol for a period of time sufficient to convert it into Form VIII and
b) recovering Form VIII from the suspension.
43. The process of claim 42 wherein the atorvastatin hemi-calcium is Form V.
44. The process of claim 42 wherein the atorvastatin hemi-calcium is Form XII.
45. The process of claim 42 wherein the atorvastatin hemi-calcium is Form I.
46. The process of claim 42 wherein the ethanol contains about 0.5% or less water.
47. The process of claim 46 wherein the ethanol contains about 0.2% or less water.
48. The process of claim 42 wherein the temperature of the suspension is elevated to about 78° C. before Form VIII is recovered from the suspension.
49. The process of claim 48 further comprising adding methanol to the suspension before recovering Form VIII to improve the chemical purity of Form VIII recovered from the suspension.
50. Atorvastatin hemi-calcium Form IX and hydrates thereof having a powder X-ray diffraction pattern substantially as depicted in FIG. 6.
51. The atorvastatin hemi-calcium Form IX of claim 50 and hydrates thereof characterized by its powder X-ray diffraction pattern having peaks at 19.1, 19.9, 21.4, 22.5, 23.5±0.2 degrees 2θ.
52. The atorvastatin hemi-calcium Form IX and hydrates thereof of claim 51 further characterized by its powder X-ray diffraction pattern having peaks at 6.9, 17.0, 17.4, 18.2, 18.6±0.2 degrees two-theta.
53. The atorvastatin hemi-calcium Form IX and hydrates thereof of claim 51 containing up to 7% water.
54. An atorvastatin hemi-calcium Form IX hydrate of claim 51 containing from about one to about four moles of water.
55. The atorvastatin hemi-calcium Form IX and hydrates thereof of claim 51 having a narrow particle size distribution.
56. The atorvastatin hemi-calcium Form IX and hydrates thereof of claim 55 wherein all of the particles are 100 microns or less in diameter.
57. The atorvastatin hemi-calcium Form IX and hydrates thereof of claim 56 wherein all of the particles are 50 microns or less in diameter.
58. Atorvastatin hemi-calcium Form IX and hydrates thereof with d-spacings of about 30.86, 18.67, 16.91, 15.17, 12.66, 11.20, 9.50, 9.28, 8.63, 7.69, 7.38, 6.51, 5.45, 5.26, 5.20, 5.12, 4.87, 4.76, 4.63, 4.47, 4.14, 4.08, 3.78, 3.73, 3.62, and 3.58 angstroms.
59. The atorvastatin hemi-calcium Form IX and hydrates thereof of claim 58 that produce a high resolution X-ray powder diffraction pattern substantially as shown in FIG. 7 when irradiated with X-rays with a wavelength of about 1.15 angstroms.
60. The atorvastatin hemi-calcium Form IX and hydrates thereof of claim 58 having monoclinic unit cell with the following unit cell parameters: a18.75-18.85 Å, b=5.525-5.54 Å, c=30.9-31.15 Å and β=96.5 to 97.5°.
61. Atorvastatin hemi-calcium Form IX and hydrates thereof having a solid state 13C nuclear magnetic resonance spectrum substantially as depicted in FIG. 8.
62. The atorvastatin hemi-calcium Form IX and hydrates thereof of claim 61 further characterized by solid-state 13C nuclear magnetic resonances at 24.9, 26.1, 119.5, 120.2, 121.7, 122.8, 126.7, 128.6, 129.4, 134.3, 135.1, 136.8, 138.3 and 139.4 parts per million.
63. The atorvastatin hemi-calcium Form IX and hydrates thereof of claim 62 characterized by solid-state 13C nuclear magnetic resonances at 18.0, 20.4, 24.9, 26.1, 40.4, 46.4, 71.0, 73.4, 114.3, 116.0, 119.5, 120.2, 121.7, 122.8, 126.7, 128.6, 129.4, 134.3, 135.1, 136.8, 138.3, 139.4, 159.9, 166.3, 178.4 and 186.6 parts per million.
64. The atorvastatin hemi-calcium Form IX and hydrates thereof of claim 61 having the following chemical shift differences between the lowest resonance and other resonances: 2.4, 6.9, 8.1, 22.4, 28.4, 53.0, 55.4, 96.3, 98.0, 101.5, 102.2, 103.7, 104.8, 108.7, 110.6, 111.4, 116.3, 117.1, 118.8, 120.3, 121.4, 141.9, 148.3, 160.4 and 168.6 parts per million.
65. Atorvastatin hemi-calcium Form IX butanolate.
66. Atorvastatin hemi-calcium Form IX containing up to about 5% butanol.
67. A process for preparing atorvastatin hemi-calcium Form IX and solvates thereof comprising the steps of:
a) suspending any other crystalline or amorphous form of atorvastatin hemi-calcium in 1-butanol for a period of time sufficient to convert the other form to Form IX and
b) recovering Form IX from the suspension.
68. The process of claim 67 wherein the other form is Form I.
69. The process of claim 67 wherein the other form is Form V.
70. The process of claim 42 wherein the other form is Form XII.
71. The process of claim 67 wherein the temperature of the suspension is elevated to the reflux temperature of 1-butanol before recovering Form IX from the suspension.
72. The process of claim 67 wherein the time sufficient to convert the other form to Form IX is about half an hour or less.
73. The process of claim 67 further comprising the step of adding an anti-solvent to the suspension before recovering Form IX in order to increase the amount of Form IX recovered from the suspension.
74. The process of claim 73 wherein the anti-solvent is selected from the group consisting of n-hexane, isopropanol and water.
75. A process for preparing atorvastatin hemi-calcium Form IX from Form VIII by exposing atorvastatin hemi-calcium Form VIII to an atmosphere of from about 80% to about 100% relative humidity.
76. The process of claim 75 wherein the Form VIII is exposed to the humid atmosphere for about 9 days or less.
77. The process of claim 75 wherein the Form VIII is exposed to the humid atmosphere at room temperature.
78. A process for preparing atorvastatin hemi-calcium Form IX comprising the steps of:
a) suspending Form VIII atorvastatin hemi-calcium in ethanol for a period of time sufficient to convert the other form into Form IX and
b) recovering Form IX from the suspension.
79. The process of claim 78 wherein the ethanol contains about 0.5% or less water.
80. The process of claim 79 wherein the ethanol contains about 0.2% or less water.
81. The process of claim 78 wherein the temperature of the suspension is maintained at about room temperature over the time period in which the other form is converted into Form IX.
82. The process of claim 78 wherein the time period sufficient to convert the other form into Form IX is about 16 hours.
83. Atorvastatin hem-calcium Form X and solvates thereof having a powder X-ray diffraction pattern substantially as depicted in FIG. 9.
84. Atorvastatin hemi-calcium Form X and solvates thereof of claim 83 characterized by a powder X-ray diffraction pattern having sharp peaks at 19.1 and 19.4±0.2 degrees 2 and other peaks at 20.0 and 20.8±0.2 degrees 2θ.
85. The atorvastatin hemi-calcium Form X and solvates thereof of claim 84 further characterized by having peaks at 222.8, 23.6 and 25.0±0.2 degrees 2 in its powder X-ray diffraction pattern.
86. The atorvastatin hemi-calcium Form X and solvates thereof of claim 83 containing up to about 5% water.
87. The atorvastatin hemi-calcium Form X and solvates thereof of claim 83 containing one to three moles of water.
88. Atorvastatin hemi-calcium Form X and solvates thereof containing up to about 2% ethanol.
89. The atorvastatin hemi-calcium Form X and solvates thereof of claim 83 having a narrow particle size distribution.
90. The atorvastatin hemi-calcium Form X and solvates thereof of claim 89 wherein all of the particles are 100 microns or less in diameter.
91. The atorvastatin hemi-calcium Form X and solvates thereof of claim 90 wherein all of the particles are 50 microns or less in diameter.
92. Atorvastatin hemi-calcium Form X and solvates thereof with d-spacings of about 30.63, 18.49, 16.66, 15.12, 12.49, 11.19, 10.20, 9.38, 9.24, 9.13, 8.58, 7.64, 7.36, 7.26, 6.81, 6.50, 6.16, 5.91, 5.24, 5.19, 5.06, 4.86, 4.74, 4.65, 4.61, 4.56, 4.12, 4.05, 3.93, 3.90, and 3.77 angstroms.
93. The atorvastatin hemi-calcium Form X and solvates thereof of claim 92 that produce a high resolution X-ray powder diffraction pattern substantially as shown in FIG. 10 when irradiated with X-rays with a wavelength of about 1.15 angstroms.
94. The atorvastatin hemi-calcium Form X and solvates thereof of claim 92 having a monoclinic unit cell with the following unit cell parameters: a=18.55-18.65 Å, b=5.52-5.53 Å, c=30.7-30.85 Å and β=95.7 to 96.7°.
95. Atorvastatin hemi-calcium Form X and solvates thereof having a solid state 13C nuclear magnetic resonance spectrum substantially as depicted in FIG. 11.
96. The atorvastatin hemi-calcium Form X and solvates thereof of claim 95 further characterized by solid-state 13C nuclear magnetic resonances at 24.9, 119.5, 122.4, 126.7, 128.9, 134.5, 138.0, 159.4 and 166.2 parts per million.
97. The atorvastatin hemi-calcium Form X and solvates thereof of claim 96 characterized by solid-state 13C nuclear magnetic resonances at 17.7, 18.7, 19.6, 20.6, 24.9, 43.4, 63.1, 66.2, 67.5, 71.1, 115.9, 119.5, 122.4, 126.7, 128.9, 134.5, 138.0, 159.4, 166.2, 179.3, 181.1, 184.3 and 186.1 parts per million.
98. The atorvastatin hemi-calcium Form X and solvates thereof of claim 95 having the following chemical shift differences between the lowest resonance and other resonances: 1.0, 1.9, 2.9, 7.2, 25.7, 45.4, 48.5, 49.8, 53.4, 98.2, 101.8, 104.7, 109.0, 111.2, 116.8, 120.3, 141.7, 148.5, 161.6, 163.4, 166.6 and 168.4 parts per million.
99. A process for preparing atorvastatin hemi-calcium Form X comprising the steps of:
a) suspending any other crystalline or amorphous form of atorvastatin hemi-calcium in a mixture of ethanol and water for a period of time sufficient to convert the other form into Form X and
b) recovering Form X from the suspension.
100. The process of claim 99 wherein the suspension is heated to the reflux temperature of the ethanol-water mixture before recovery of Form X from the suspension.
101. The process of claim 99 wherein the time sufficient to convert the other form into Form X is about an hour.
102. The process of claim 99 wherein the mixture contains about six parts ethanol to one part water.
103. The process of claim 99 wherein the mixture contains about five parts ethanol to one part water.
104. Atorvastatin hemi-calcium Form XI and solvates thereof having a powder X-ray diffraction pattern substantially as depicted in FIG. 12.
105. The atorvastatin hemi-calcium Form XI and solvates thereof of claim 104 characterized by PXRD peaks at 3.2, 3.7, 5.1, 6.3, 7.8, 8.6, 9.8, 11.2, 11.8, 12.4, 15.4, 18.7, 19.9, 24.0±0.2 degrees two-theta.
106. The atorvastatin hemi-calcium Form XI and solvates thereof of claim 104 having a narrow particle size distribution.
107. The atorvastatin hemi-calcium Form XI and solvates thereof of claim 106 wherein all of the particles are 100 microns or less in diameter.
108. The atorvastatin hemi-calcium Form XI and solvates thereof of claim 107 wherein all of the particles are 50 microns or less in diameter.
109. A process for preparing atorvastatin hemi-calcium Form XI comprising the steps of:
a) suspending atorvastatin hemi-calcium in methyl ethyl ketone at room temperature for a period of time sufficient to cause the conversion into atorvastatin hemi-calcium Form XI, and
b) recovering atorvastatin hemi-calcium Form XI from the suspension.
110. The process for preparing atorvastatin hemi-calcium Form XI of claim 109 wherein the atorvastatin hemi-calcium is Form V.
111. A process for preparing atorvastatin hemi-calcium Form XI comprising the steps of dissolving atorvastatin hemi-calcium in isopropyl alcohol at elevated temperature to form a solution of atorvastatin hemi-calcium, cooling the solution until it gels and then drying the gel to obtain atorvastatin hemi-calcium Form XI.
112. Atorvastatin hemi-calcium Form XII and solvates thereof characterized by a powder X-ray diffraction pattern having peaks at 8.0, 8.4, 11.8, 18.2, 19.0±0.2 degrees 2θ.
113. The atorvastatin hemi-calcium Form XII and solvates thereof of claim 112 having a narrow particle size distribution.
114. The atorvastatin hemi-calcium Form XII and solvates thereof of claim 113 wherein all of the particles are 100 microns or less in diameter.
115. The atorvastatin hemi-calcium Form XII and solvates thereof of claim 114 wherein all of the particles are 50 microns or less in diameter.
116. A process for preparing atorvastatin hemi-calcium Form XII comprising the steps of:
a) suspending [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dioxane-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoic ester in ethanol,
b) deprotecting the [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dioxane-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoic ester by adding hydrochloric acid to the suspension, thereby forming a solution of atorvastatin ester derivatives in ethanol,
c) adding calcium hydroxide to the solution, thereby forming a solution of atorvastatin hemi-calcium in ethanol,
d) optionally removing any excess calcium hydroxide, and
e) precipitating atorvastatin hemi-calcium from the solution as Form XII.
117. A process for preparing atorvastatin hemi-calcium Form I comprising the steps of:
a) suspending any other form of atorvastatin hemi-calcium in water for a period of time sufficient to convert the other form into Form I and
b) recovering Form I from the suspension.
118. A process for preparing atorvastatin hemi-calcium Form II comprising the steps of:
a) suspending [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dioxane-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoic ester in methanol,
b) deprotecting the [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dioxane-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoic ester by adding hydrochloric acid to the suspension, thereby forming a solution of atorvastatin ester derivatives in methanol,
c) adding calcium hydroxide to the solution, thereby forming a solution of atorvastatin hemi-calcium in methanol,
d) optionally removing any excess calcium hydroxide, and
e) precipitating atorvastatin hemi-calcium from the solution as Form II.
119. A process for preparing amorphous hemi-calcium comprising the steps of:
a) suspending a crystalline form of atorvastatin hemi-calcium in acetonitrile,
b) sonicating the suspension for a period of time sufficient to convert the crystalline form to amorphous atorvastatin hemi-calcium, and
c) recovering amorphous atorvastatin hemi-calcium from the suspension.
120. The process of claim 119 wherein the crystalline form of atorvastatin hemi-calcium is Form VII.
121. The process of claim 119 wherein the crystalline form of atorvastatin hemi-calcium is Form I.
122. The process of claim 119 wherein the suspension is sonicated for a period of from about 1 to about 3 minutes.
123. The process of claim 119 wherein the suspension is sonicated at room temperature.
124. A process for preparing atorvastatin hemi-calcium Form IV comprising the steps of:
a) suspending atorvastatin hemi-calcium Form I in 1-butanol for a period of time sufficient to convert Form I into Form IV and
b) recovering Form IV from the suspension.
125. The process of claim 124 wherein the suspension is maintained at room temperature for the period time in which Form I is converted into Form IV.
126. The process of claim 124 wherein the time sufficient to convert Form I into Form IV is about 24 h.
127. A process for preparing atorvastatin hemi-calcium Form IV comprising the steps of:
a) suspending atorvastatin hemi-calcium Form V in a mixture of ethanol and water for a period of time sufficient to convert Form V into Form IV and
b) recovering Form IV from the suspension.
128. The process of claim 127 wherein the temperature of the suspension is elevated to about 50° C. before recovering Form IV from the suspension.
129. The process of claim 127 wherein the period of time sufficient to convert Form V into Form IV is about one hour.
130. The process of claim 127 wherein the mixture contains about 15% water.
131. A process of preparing atorvastatin hemi-calcium Form IV comprising the steps of:
a) suspending atorvastatin hemi-calcium Form V in methanol for a period of time sufficient to convert Form V into Form IV, and
b) recovering Form IV from the suspension.
132. The process of claim 131 wherein the suspension is maintained at a temperature of from about room temperature to the reflux temperature of methanol for the period of time in which Form Vis converted into Form IV.
133. The process of claim 131 wherein the period of time sufficient to convert the other form into Form IV is from about 1 hour to about 20 hours.
134. A process for preparing atorvastatin hemi-calcium Form V comprising the steps of:
a) suspending [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dioxane-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoic acid ester in ethanol,
b) deprotecting the [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dioxane-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoic ester by adding hydrochloric acid to the suspension, thereby forming a solution of atorvastatin lactone and [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoic acid ester in ethanol,
c) adding calcium hydroxide to the solution, thereby forming a solution of atorvastatin hemi-calcium in ethanol,
d) precipitating atorvastatin hemi-calcium from the solution, and
e) drying the precipitated atorvastatin hemi-calcium to obtain atorvastatin hemi-calcium as Form V.
135. A process for purifying atorvastatin hemi-calcium Form V comprising suspending the atorvastatin hemi-calcium Form V in a mixture of ethanol and water and recovering Form V from the mixture in greater purity.
136. The process of claim 135 wherein the mixture comprises from about 10% water and about 90% ethanol by volume.
137. A process for preparing amorphous atorvastatin hemi-calcium comprising the steps of:
a) contacting any crystalline form of atorvastatin hemi-calcium with acetone for a period of time sufficient to convert the crystalline form into amorphous atorvastatin hemi-calcium and
b) separating solid amorphous atorvastatin hemi-calcium from the acetone.
138. The process for preparing amorphous atorvastatin hemi-calcium of claim 137 wherein the crystalline form of atorvastatin hemi-calcium dissolves in the acetone to yield a substantially clear solution and further wherein solid amorphous atorvastatin hemi-calcium is precipitated from the substantially clear solution.
139. A process of claim 137 wherein the crystalline form of atorvastatin hemi-calcium is Form V.
140. The process of claim 137 wherein the crystalline form of atorvastatin hemi-calcium and acetone are contacted at room temperature.
141. The process of claim 137 wherein the period of time sufficient to convert the crystalline form into amorphous atorvastatin hemi-calcium is about 16 hours.
142. A process for preparing amorphous atorvastatin hemi-calcium by ball milling any crystalline form of atorvastatin hemi-calcium.
143. The process of claim 142 wherein the crystalline form of atorvastatin hemi-calcium is selected from the group consisting of Form I, Form V and Form VIII.
144. A pharmaceutical composition comprising atorvastatin hemi-calcium Form VI, VIII, IX, X, XI, XII or a mixture thereof.
145. Use of atorvastatin Form VI, VIII, IX, X, XI, XII or mixtures thereof, to prepare a pharmaceutical dosage form.
146. A pharmaceutical dosage form comprising atorvastatin hemi-calcium Form VI, VIII, IX, X, XI, XII or mixtures thereof.
US09/997,126 2000-11-30 2001-11-29 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms Abandoned US20020183378A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US25007200P true 2000-11-30 2000-11-30
US26789701P true 2001-02-09 2001-02-09
US28187201P true 2001-04-05 2001-04-05
US31214401P true 2001-08-13 2001-08-13
US32652901P true 2001-10-01 2001-10-01
US09/997,126 US20020183378A1 (en) 2000-11-30 2001-11-29 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US09/997,126 US20020183378A1 (en) 2000-11-30 2001-11-29 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US10/370,897 US7501450B2 (en) 2000-11-30 2003-02-19 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US10/901,845 US6992194B2 (en) 2000-11-30 2004-07-28 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US10/994,142 US7144916B2 (en) 2000-11-30 2004-11-19 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/193,112 US7189861B2 (en) 2000-11-30 2005-07-29 Processes for preparing amorphous atorvastatin hemi-calcium
US11/193,089 US7256212B2 (en) 2000-11-30 2005-07-29 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/192,707 US7151183B2 (en) 2000-11-30 2005-07-29 Processes for preparing amorphous atorvastatin hemi-calcium
US11/192,674 US7456297B2 (en) 2000-11-30 2005-07-29 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/192,672 US7161012B2 (en) 2000-11-30 2005-07-29 Processes for preparing amorphous atorvastatin hemi-calcium
US11/233,310 US20060020137A1 (en) 2001-11-29 2005-09-21 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,979 US7468444B2 (en) 2000-11-30 2005-10-24 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,821 US7342120B2 (en) 2000-11-30 2005-10-24 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,815 US20060106232A1 (en) 2000-11-30 2005-10-24 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,828 US7488750B2 (en) 2000-11-30 2005-10-24 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,808 US20060106231A1 (en) 2000-11-30 2005-10-24 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,886 US20060100267A1 (en) 2000-11-30 2005-10-24 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/977,387 US20080214650A1 (en) 2000-11-30 2007-10-23 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel process for preparing other forms
US12/286,594 US20090143459A1 (en) 2000-11-30 2008-09-30 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/370,897 Continuation-In-Part US7501450B2 (en) 2000-11-30 2003-02-19 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US10/901,845 Division US6992194B2 (en) 2000-11-30 2004-07-28 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US10/994,142 Division US7144916B2 (en) 2000-11-30 2004-11-19 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Publications (1)

Publication Number Publication Date
US20020183378A1 true US20020183378A1 (en) 2002-12-05

Family

ID=27540285

Family Applications (15)

Application Number Title Priority Date Filing Date
US09/997,126 Abandoned US20020183378A1 (en) 2000-11-30 2001-11-29 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US10/901,845 Expired - Fee Related US6992194B2 (en) 2000-11-30 2004-07-28 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US10/994,142 Expired - Fee Related US7144916B2 (en) 2000-11-30 2004-11-19 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/193,089 Expired - Fee Related US7256212B2 (en) 2000-11-30 2005-07-29 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/192,674 Expired - Fee Related US7456297B2 (en) 2000-11-30 2005-07-29 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/192,672 Expired - Fee Related US7161012B2 (en) 2000-11-30 2005-07-29 Processes for preparing amorphous atorvastatin hemi-calcium
US11/192,707 Expired - Fee Related US7151183B2 (en) 2000-11-30 2005-07-29 Processes for preparing amorphous atorvastatin hemi-calcium
US11/193,112 Expired - Fee Related US7189861B2 (en) 2000-11-30 2005-07-29 Processes for preparing amorphous atorvastatin hemi-calcium
US11/257,821 Expired - Fee Related US7342120B2 (en) 2000-11-30 2005-10-24 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,815 Abandoned US20060106232A1 (en) 2000-11-30 2005-10-24 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,808 Abandoned US20060106231A1 (en) 2000-11-30 2005-10-24 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,828 Expired - Fee Related US7488750B2 (en) 2000-11-30 2005-10-24 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,886 Abandoned US20060100267A1 (en) 2000-11-30 2005-10-24 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,979 Expired - Fee Related US7468444B2 (en) 2000-11-30 2005-10-24 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/977,387 Abandoned US20080214650A1 (en) 2000-11-30 2007-10-23 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel process for preparing other forms

Family Applications After (14)

Application Number Title Priority Date Filing Date
US10/901,845 Expired - Fee Related US6992194B2 (en) 2000-11-30 2004-07-28 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US10/994,142 Expired - Fee Related US7144916B2 (en) 2000-11-30 2004-11-19 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/193,089 Expired - Fee Related US7256212B2 (en) 2000-11-30 2005-07-29 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/192,674 Expired - Fee Related US7456297B2 (en) 2000-11-30 2005-07-29 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/192,672 Expired - Fee Related US7161012B2 (en) 2000-11-30 2005-07-29 Processes for preparing amorphous atorvastatin hemi-calcium
US11/192,707 Expired - Fee Related US7151183B2 (en) 2000-11-30 2005-07-29 Processes for preparing amorphous atorvastatin hemi-calcium
US11/193,112 Expired - Fee Related US7189861B2 (en) 2000-11-30 2005-07-29 Processes for preparing amorphous atorvastatin hemi-calcium
US11/257,821 Expired - Fee Related US7342120B2 (en) 2000-11-30 2005-10-24 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,815 Abandoned US20060106232A1 (en) 2000-11-30 2005-10-24 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,808 Abandoned US20060106231A1 (en) 2000-11-30 2005-10-24 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,828 Expired - Fee Related US7488750B2 (en) 2000-11-30 2005-10-24 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,886 Abandoned US20060100267A1 (en) 2000-11-30 2005-10-24 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/257,979 Expired - Fee Related US7468444B2 (en) 2000-11-30 2005-10-24 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US11/977,387 Abandoned US20080214650A1 (en) 2000-11-30 2007-10-23 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel process for preparing other forms

Country Status (23)

Country Link
US (15) US20020183378A1 (en)
EP (5) EP2192113A1 (en)
JP (2) JP2004514694A (en)
KR (1) KR100765871B1 (en)
CN (1) CN1489463A (en)
AU (1) AU1792702A (en)
BG (1) BG107856A (en)
BR (1) BR0115892A (en)
CA (3) CA2429590C (en)
CZ (1) CZ20031766A3 (en)
DE (1) DE01998348T1 (en)
ES (2) ES2437157T3 (en)
HR (2) HRP20030523A2 (en)
HU (1) HU0600538A3 (en)
IL (2) IL156055D0 (en)
IS (1) IS6829A (en)
MX (1) MXPA03004844A (en)
NO (1) NO20032425L (en)
PL (1) PL363228A1 (en)
SK (1) SK8062003A3 (en)
TR (1) TR200400815T3 (en)
WO (1) WO2002043732A1 (en)
YU (1) YU42803A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070665A2 (en) * 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Desolvating solvates of atorvastatin hemi-calcium
US20050131055A1 (en) * 2002-02-01 2005-06-16 Leciva, A.S. Method of manufacturing an amorphous form of the hemi-calcium salt of (3r, 5r) 7-3-phenly-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (actorvastatin)
WO2006012499A2 (en) * 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
WO2006037125A1 (en) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Process for preparing forms of atorvastatin calcium substantially free of impurities
WO2006045018A1 (en) 2004-10-18 2006-04-27 Teva Pharmaceutical Industries Ltd. Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent
US20070032665A1 (en) * 2005-08-04 2007-02-08 Srinivasulu Gudipati Preparation of atorvastatin calcium form i
WO2007070667A2 (en) * 2005-12-13 2007-06-21 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US20090208539A1 (en) * 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
US7923467B2 (en) 2003-05-30 2011-04-12 Ranbaxy Laboratories, Inc. Substituted pyrrole derivatives and their use as HMG-CO inhibitors
US7956198B2 (en) 2005-11-08 2011-06-07 Ranbaxy Laboratories, Limited Pharmaceutical compositions
US7994343B2 (en) 2004-03-17 2011-08-09 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE36268E (en) * 1988-03-15 1999-08-17 Boehringer Mannheim Corporation Method and apparatus for amperometric diagnostic analysis
EP1332130A4 (en) * 2000-11-03 2004-01-21 Teva Pharma Atorvastatin hemi-calcium form vii
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
KR100877165B1 (en) * 2000-11-16 2009-01-07 테바 파마슈티컬 인더스트리즈 리미티드 Hydrolysis of [??*,?*]-2-4-fluorophenyl-?,?-dihydroxy-5-1-methylethyl-3-phenyl-4-[phenylaminocarbonyl]-1?-pyrrole-1-heptanoic acid esters with calcium hydroxide
AU2002324715B2 (en) * 2001-08-16 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
IL156055D0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
KR100790766B1 (en) 2000-12-27 2008-01-03 테바 파마슈티컬 인더스트리즈 리미티드 Crystalline forms of Atorvastatin, a process for the preparation thereof and a pharmaceutical composition comprising the same
CN101215253A (en) * 2001-06-29 2008-07-09 沃纳-兰伯特公司 Crystalline forms of atorvastatin
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
EE200400048A (en) * 2001-07-30 2004-04-15 Dr. Reddy's Laboratories Ltd. Crystalline forms of atorvastatin VI and VII
KR100724515B1 (en) * 2002-02-15 2007-06-04 테바 파마슈티컬 인더스트리즈 리미티드 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
AU2002356423A1 (en) * 2002-05-28 2003-12-12 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20060122403A1 (en) * 2002-09-03 2006-06-08 Sanjay Suri Atorvastatin calcium form vi or hydrates thereof
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
WO2004050618A2 (en) * 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
UY28501A1 (en) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
ITMI20032144A1 (en) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Polymorphic forms of rifaximin, and processes for obtaining them
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
CA2564030C (en) 2004-05-05 2010-06-08 Pfizer Products Inc. Salt forms of [r-(r*, r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
CA2567931A1 (en) * 2004-05-24 2005-12-08 Warner-Lambert Company Llc Salt forms of atorvastatin
WO2006008091A2 (en) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
US8026376B2 (en) * 2004-07-20 2011-09-27 Pfizer, Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoicacid calcium salt (2:1)
CA2582449A1 (en) * 2004-09-30 2006-04-13 Dr. Reddy's Laboratories Ltd. Amorphous atorvastatin calcium
MX2007004722A (en) 2004-10-28 2007-06-15 Warner Lambert Co Process for forming amorphous atorvastatin.
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
PT1698630E (en) 2005-03-03 2014-09-15 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
WO2006106372A1 (en) * 2005-04-08 2006-10-12 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság New crystalline atorvastatin hemicalcium salt polymorph form
ES2270722B1 (en) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedure for obtaining amorphous atorvastatin calcium.
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
EP1808162A1 (en) 2005-11-21 2007-07-18 Teva Pharmaceutical Industries Ltd. Atorvastatin pharmaceutical formulation
EP1923057A1 (en) 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Atorvastatin pharmaceutical formulation
WO2007057755A1 (en) * 2005-11-21 2007-05-24 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
JP2007246514A (en) * 2006-02-14 2007-09-27 Toyama Chem Co Ltd Novel crystal of piperacillin sodium
WO2007096903A2 (en) * 2006-02-22 2007-08-30 Matrix Laboratories Ltd New crystalline form of atorvastatin hemi-calcium
US20070249845A1 (en) * 2006-03-01 2007-10-25 Michael Pinchasov Process for preparing a crystalline form of atorvastatin hemi-calcium
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CN100406438C (en) 2006-06-30 2008-07-30 浙江新东港药业股份有限公司;浙江大学 Preparation method of amorphous atorvastatin calcium
AU2007274724B2 (en) * 2006-07-14 2012-07-26 Ranbaxy Laboratories Limited Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
US20100029743A1 (en) * 2006-09-27 2010-02-04 Dr. Reddy's Laboratories Ltd. Atorvastatin pharmaceutical compositions
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
RU2009132516A (en) * 2007-01-31 2011-03-10 Тояма Кемикал Ко., Лтд. (Jp) The new crystalline form piperatsillinnatriya
CA2679317A1 (en) 2007-03-02 2008-09-12 Dong-A Pharm. Co., Ltd. Novel crystal forms of pyrrolylheptanoic acid derivatives
WO2008129562A2 (en) * 2007-04-20 2008-10-30 Morepen Laboratories Limited An improved process for the preparation of stable amorphous atorvastatin hemi calcium and their salts thereof
US20100204195A1 (en) * 2007-07-27 2010-08-12 Cipla Limited Pharmaceutical Compositions and Process for Making Them
WO2009082362A1 (en) * 2007-11-05 2009-07-02 Ulkar Kimya San. Ve Tic. A.S. A method for producing statins in pure form
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN101538237B (en) * 2008-05-30 2011-04-06 天津和美生物技术有限公司 Atorvastatin semi-calcium salt butanone co-crystallization substances, preparation and application thereof as HMG-CoA enzyme inhibitor
EP2303474B1 (en) 2008-07-17 2014-10-15 DeLaval Holding AB Method of cleaning food and beverage manufacturing and handling equipmemt
US9334266B2 (en) 2009-09-04 2016-05-10 The University Of Toledo Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby
IT1398550B1 (en) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulations comprising rifaximin useful to get a long-lasting effect
KR20120011249A (en) 2010-07-28 2012-02-07 주식회사 경보제약 Novel Crystal Form of Atorvastatin Hemi-Calcium, Hydrate thereof, and Method of Producing the Same
ITBO20120368A1 (en) 2012-07-06 2014-01-07 Alfa Wassermann Spa Compositions comprising rifaximin and amino acids, of rifaximin crystals resulting from these compositions and their use.
CN102766136A (en) * 2012-08-07 2012-11-07 浙江宏元药业有限公司 Method for preparing atorvastatin calcium intermediate
CN105111123A (en) * 2013-11-25 2015-12-02 李兴惠 Atorvastatin calcium and composition
CN104945300B (en) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 A Type Ⅰ purification process statins atorvastatin calcium
EP3272336A1 (en) * 2016-07-19 2018-01-24 Stada Arzneimittel Ag Atorvastatin composition

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5273995A (en) * 1989-07-21 1993-12-28 Warner-Lambert Company [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
US5686104A (en) * 1993-01-19 1997-11-11 Warner-Lambert Company Stable oral CI-981 formulation and process of preparing same
US5969156A (en) * 1995-07-17 1999-10-19 Warner-Lambert Company Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US6121461A (en) * 1995-07-17 2000-09-19 Warner-Lambert Company Form III crystalline [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
US6528661B2 (en) * 2000-11-16 2003-03-04 Teva Pharmaceutical Industries Ltd. Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
US6605728B2 (en) * 1999-12-17 2003-08-12 Warner-Lambert Company Process for producing crystalline atorvastatin calcium
US6605636B2 (en) * 2000-11-03 2003-08-12 Teva Pharmaceutical Industries Ltd. Atorvastatin hemi-calcium form VII
US6605729B1 (en) * 2001-06-29 2003-08-12 Warner-Lambert Company Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US115709A (en) * 1871-06-06 Improvement in curriers slickers
US99224A (en) * 1870-01-25 Improvement in pocket-sates for friction-matches
US2598627A (en) * 1949-10-11 1952-05-27 Robert Gair Co Inc Folding carton
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE4411536A1 (en) * 1994-04-02 1995-10-05 Cassella Ag Water-swellable hydrophilic polymers
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6065729A (en) * 1998-01-28 2000-05-23 Prince Corporation Slide-out container holder
US5959156A (en) 1998-11-12 1999-09-28 Bp Amoco Corporation Preparation of polyoxymethylene dimethyl ethers by catalytic conversion of dimethyl ether with formaldehyde formed by oxy-dehydrogenation of dimethyl ether
IN191236B (en) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd Process for the production of amorphous atorvastatin calcium
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
AU783002B2 (en) * 1999-11-17 2005-09-15 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (en) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemičnih izdelkov d.d. Preparation of amorphous atorvastatin
AU776613B2 (en) 1999-12-17 2004-09-16 Pfizer Science And Technology Ireland Limited A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt
JP4364650B2 (en) 2002-03-28 2009-11-18 イーエムシー コーポレイションEmc Corporation Data storage system
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
AU2002324715B2 (en) * 2001-08-16 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
IL156055D0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
KR100790766B1 (en) * 2000-12-27 2008-01-03 테바 파마슈티컬 인더스트리즈 리미티드 Crystalline forms of Atorvastatin, a process for the preparation thereof and a pharmaceutical composition comprising the same
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (en) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Preparation of amorphous atorvastatin
SI20848A (en) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Pharmaceutical formulation containing atorvastatin calcium
IN190564B (en) 2001-04-11 2003-08-09 Cadila Heathcare Ltd Process for the production of atorvastatin calciumin amorphous form
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
EE200400048A (en) 2001-07-30 2004-04-15 Dr. Reddy's Laboratories Ltd. Crystalline forms of atorvastatin VI and VII
AU2001284385A1 (en) 2001-08-31 2003-03-10 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
US7141662B2 (en) 2001-11-30 2006-11-28 University Of Maryland, Baltimore Nucleic acids encoding novel proteins in enteroaggregative Escherichia coli (EAEC)
US20050209306A1 (en) * 2001-12-12 2005-09-22 Alexandr Jegorov Crystalline [R-(R*,R*)]-2-(4-fluorophenyI)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl- 4-[(phenylamino)carbonyl]-1H-pyrrole-heptanoic acid calcium salt (2:1)
KR100724515B1 (en) 2002-02-15 2007-06-04 테바 파마슈티컬 인더스트리즈 리미티드 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
KR20040086397A (en) 2002-02-19 2004-10-08 테바 파마슈티컬 인더스트리즈 리미티드 Desolvating solvates of atorvastatin hemi-calcium
AU2002356423A1 (en) * 2002-05-28 2003-12-12 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US20060122403A1 (en) * 2002-09-03 2006-06-08 Sanjay Suri Atorvastatin calcium form vi or hydrates thereof
SI21302A (en) 2002-10-11 2004-04-30 LEK farmacevtska družba d.d. Stabilized pharmaceutical product with amorphous active ingredient
WO2004050618A2 (en) 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
US20040242670A1 (en) * 2003-06-02 2004-12-02 Sonny Sebastian Process for preparation of amorphous atorvastatin calcium
DE05774589T1 (en) * 2004-07-22 2007-08-09 Teva Pharmaceutical Industries Ltd. New crystal forms of atorvastatin hemi-calcium and processes for their preparation
KR20090033405A (en) * 2004-10-18 2009-04-02 테바 파마슈티컬 인더스트리즈 리미티드 Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent
US20070032665A1 (en) * 2005-08-04 2007-02-08 Srinivasulu Gudipati Preparation of atorvastatin calcium form i

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5273995A (en) * 1989-07-21 1993-12-28 Warner-Lambert Company [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
US5686104A (en) * 1993-01-19 1997-11-11 Warner-Lambert Company Stable oral CI-981 formulation and process of preparing same
US5969156A (en) * 1995-07-17 1999-10-19 Warner-Lambert Company Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
US6121461A (en) * 1995-07-17 2000-09-19 Warner-Lambert Company Form III crystalline [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US6605728B2 (en) * 1999-12-17 2003-08-12 Warner-Lambert Company Process for producing crystalline atorvastatin calcium
US6605636B2 (en) * 2000-11-03 2003-08-12 Teva Pharmaceutical Industries Ltd. Atorvastatin hemi-calcium form VII
US6528661B2 (en) * 2000-11-16 2003-03-04 Teva Pharmaceutical Industries Ltd. Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
US6605729B1 (en) * 2001-06-29 2003-08-12 Warner-Lambert Company Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050131055A1 (en) * 2002-02-01 2005-06-16 Leciva, A.S. Method of manufacturing an amorphous form of the hemi-calcium salt of (3r, 5r) 7-3-phenly-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (actorvastatin)
US7208608B2 (en) * 2002-02-01 2007-04-24 Zentiva A. S. Method of manufacturing an amorphous form of the hemi-calcium salt of (3R,5R) 7-3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yll-3, 5-dihydroxyheptanoic acid (actorvastatin)
US20070027328A1 (en) * 2002-02-19 2007-02-01 Judith Aronhime Processes for desolvating solvates of atorvastatin hemi-calcium and atorvastatin hem-calcium essentially free of organic solvent
US20030216584A1 (en) * 2002-02-19 2003-11-20 Judith Aronhime Processes for desolvating solvates of atorvastatin hemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent
WO2003070665A3 (en) * 2002-02-19 2004-02-12 Teva Pharma Desolvating solvates of atorvastatin hemi-calcium
US7122681B2 (en) 2002-02-19 2006-10-17 Teva Pharmaceutical Industries, Ltd. Desolvation process for the production of atorvastatin hemi-calcium essentially free of bound organic solvent
WO2003070665A2 (en) * 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Desolvating solvates of atorvastatin hemi-calcium
US7923467B2 (en) 2003-05-30 2011-04-12 Ranbaxy Laboratories, Inc. Substituted pyrrole derivatives and their use as HMG-CO inhibitors
US7994343B2 (en) 2004-03-17 2011-08-09 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
WO2006012499A3 (en) * 2004-07-22 2006-07-20 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
WO2006012499A2 (en) * 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
US7674923B2 (en) 2004-09-28 2010-03-09 Teva Pharmaceutical Industries Ltd Process for preparing forms of atorvastatin calcium substantially free of impurities
US20060142592A1 (en) * 2004-09-28 2006-06-29 Nina Finkelstein Process for preparing forms of atorvastatin calcium substantially free of impurities
WO2006037125A1 (en) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Process for preparing forms of atorvastatin calcium substantially free of impurities
US20060106230A1 (en) * 2004-10-18 2006-05-18 Michael Pinchasov Processes for preparing amorphous atorvastatin hemi-calcium
WO2006045018A1 (en) 2004-10-18 2006-04-27 Teva Pharmaceutical Industries Ltd. Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent
US20090208539A1 (en) * 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
US20070032665A1 (en) * 2005-08-04 2007-02-08 Srinivasulu Gudipati Preparation of atorvastatin calcium form i
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
US7956198B2 (en) 2005-11-08 2011-06-07 Ranbaxy Laboratories, Limited Pharmaceutical compositions
US8026377B2 (en) 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US20070232683A1 (en) * 2005-12-13 2007-10-04 Michael Pinchasov Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
WO2007070667A3 (en) * 2005-12-13 2007-08-02 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
WO2007070667A2 (en) * 2005-12-13 2007-06-21 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof

Also Published As

Publication number Publication date
EP1363621A4 (en) 2005-12-28
HRP20130545A2 (en) 2013-11-08
US7488750B2 (en) 2009-02-10
HRP20030523A2 (en) 2005-06-30
US7189861B2 (en) 2007-03-13
US6992194B2 (en) 2006-01-31
US20050004206A1 (en) 2005-01-06
EP1783113A3 (en) 2007-05-30
ES2215495T1 (en) 2004-10-16
KR20030059297A (en) 2003-07-07
JP2009120624A (en) 2009-06-04
US7144916B2 (en) 2006-12-05
US20050090542A1 (en) 2005-04-28
US20060100267A1 (en) 2006-05-11
CA2689915A1 (en) 2002-06-06
US20080214650A1 (en) 2008-09-04
CN1489463A (en) 2004-04-14
AU1792702A (en) 2002-06-11
EP2194041A1 (en) 2010-06-09
EP1783113A2 (en) 2007-05-09
YU42803A (en) 2006-05-25
ES2437157T3 (en) 2014-01-09
US20050261361A1 (en) 2005-11-24
IS6829A (en) 2003-05-27
US20060106231A1 (en) 2006-05-18
BR0115892A (en) 2003-10-28
JP2004514694A (en) 2004-05-20
CZ20031766A3 (en) 2004-08-18
CA2429590C (en) 2008-06-10
EP2192113A1 (en) 2010-06-02
TR200400815T3 (en) 2004-07-21
US7161012B2 (en) 2007-01-09
SK8062003A3 (en) 2004-07-07
US20050261360A1 (en) 2005-11-24
US7151183B2 (en) 2006-12-19
US20060100445A1 (en) 2006-05-11
PL363228A1 (en) 2004-11-15
IL156055D0 (en) 2003-12-23
HU0600538A3 (en) 2010-09-28
US20060106232A1 (en) 2006-05-18
IL156055A (en) 2010-12-30
BG107856A (en) 2004-11-30
US20060058533A1 (en) 2006-03-16
MXPA03004844A (en) 2005-04-19
HU0600538A2 (en) 2006-09-28
US20060100446A1 (en) 2006-05-11
WO2002043732A1 (en) 2002-06-06
US7256212B2 (en) 2007-08-14
US7468444B2 (en) 2008-12-23
EP2192112A1 (en) 2010-06-02
EP1363621A1 (en) 2003-11-26
US7456297B2 (en) 2008-11-25
US20050282885A1 (en) 2005-12-22
NO20032425L (en) 2003-07-25
EP2192112B1 (en) 2013-08-28
NO20032425D0 (en) 2003-05-28
CA2429590A1 (en) 2002-06-06
DE01998348T1 (en) 2004-08-26
CA2625277A1 (en) 2002-06-06
KR100765871B1 (en) 2007-10-11
US20050261359A1 (en) 2005-11-24
US20050267198A1 (en) 2005-12-01
US7342120B2 (en) 2008-03-11

Similar Documents

Publication Publication Date Title
US6750353B2 (en) Preparation of pharmaceutically acceptable atorvastatin salts in non-crystalline form
CN1087288C (en) Crystalline [R-(R+,R+)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(5-methylethyl)-3-phenyl-4-(phenylamino) carbonyl]-1H-pyrole-1-heptanoic acid hemi-calcium salt (atorvastatin)
US7126008B2 (en) Carvedilol
JP3296563B2 (en) Embodiment ▲ III ▼ crystallinity of (R- (R ▲ top * ▼, R ▲ top * ▼)) - 2-(4-fluorophenyl)-beta, .delta.-dihydroxy-5- (1-methyl-ethyl) - -3-phenyl-4 - ((phenylamino) carbonyl)-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
FI94339B (en) Method pharmaceutically usable / R- (R *, R *) / - 2- (4-fluorophenyl) - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - / (phenylamino) carbonyl / -1 pyrrole-1-heptanoic acid and pharmaceutically acceptable salts thereof
FI115460B (en) A process for preparing 5- (2- (4- (1,2-benzisothiazol-3-yl) -1-piperazinyl) ethyl) -6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride
RU2303598C2 (en) Polymorphous forms of 1-[4-(5-cyanoindole-3-yl)butyl]-4-(2-carbamoylbenofuran-5-yl)-piperazine hydrochloride
JP4234429B2 (en) By calcium hydroxide [R (R *, R *)] - 2- (4-fluorophenyl)-beta, .delta.-dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) hydrolysis of carbonyl] -1H- pyrrole-1-heptanoic acid ester
US7514467B2 (en) Crystalline solids of carvedilol and processes for their preparation
KR100400805B1 (en) Amorphous [R- (R *, R *)] - 2- (4-fluorophenyl) -beta delta-dihydroxy-5- ) Carbonyl] -1H-pyrrole-1-heptanoic acid calcium salt (2: 1)
US7504504B2 (en) Methods of preparing aripiprazole crystalline forms
AU2002366383B2 (en) Polymorphs of clopidogrel hydrogensulfate
KR20000069595A (en) A Novel Compound Form
EP1638937B1 (en) Fluvastatin sodium crystal form xiv, processes for preparing it, compositions containing it and methods of using it
US20020086888A1 (en) Process for making amlodipine maleate
JP2003073353A6 (en) Crystalline [R- (R *, R *)] - 2- (4-fluorophenyl)-beta, .delta.-dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
ES2349364T3 (en) Process for preparing a polymorphic form of atorvastatin calcium.
US20030114479A1 (en) Novel crystal forms III, IV, V, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form I, compositions containing the new forms and methods of administering the new forms
FR2831883A1 (en) Rimonabant polymorphic form, process for preparing the same, and pharmaceutical compositions containing same
CZ20033478A3 (en) Crystal forms of calcium salt (2:1) of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptanoic acid (atorvastatin)
AU2001257213B2 (en) Zolpidem hemitartrate
PT970955E (en) Paroxetine methane sulfonate
US7241800B2 (en) Anhydrous amorphous form of fluvastatin sodium
CA2454500C (en) Crystalline forms vi and vii of atorvastatin calcium
WO2002083638A1 (en) Process for the production of atorvastatin calcium in amorphous form

Legal Events

Date Code Title Description
AS Assignment

Owner name: TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARONHIME, JUDITH;LIDOR-HADAS, RAMY;NIDDAM, VALERIE;AND OTHERS;REEL/FRAME:012921/0019;SIGNING DATES FROM 20020204 TO 20020217

Owner name: TEVA PHARMACEUTICALS USA, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEVA PHARMACEUTICAL INDUSTRIES LTD.;REEL/FRAME:012920/0988

Effective date: 20020212

AS Assignment

Owner name: TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WIZEL, SHLOMIT;REEL/FRAME:015424/0472

Effective date: 20040524

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION